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Abstract
Sepsis causes injury and dysfunction of pulmonary microvascular endothelial cells
(PMVEC), leading to pulmonary edema. Metalloproteinases, are associated with
inflammation and tissue damage, and their regulation by tissue inhibitors of
metalloproteinases (TIMPs) may protect against septic PMVEC dysfunction. Thus, I
hypothesize that murine septic PMVEC barrier dysfunction is due to disruption of the
balance between metalloproteinases and TIMPs leading to increased metalloproteinase
activity.
PMVEC were isolated from wild type (WT) and Timp3-/- mice. Timp and
metalloproteinase mRNA expression was altered under septic conditions and this was
associated with increased metalloproteinase activity. Global metalloproteinase inhibitors BB94 and TAPI-2 reduced albumin and dextran flux across septic PMVEC. Further, Timp3-/PMVEC had less cell surface intercellular adhesion molecule (ICAM) 1 vs. WT PMVEC,
which was associated with significantly impaired neutrophil-PMVEC adhesion.
Thus, my data suggest TIMPs may protect against septic PMVEC barrier dysfunction,
at least partly, through direct inhibition of metalloproteinase activity.
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Chapter 1

1

Introduction

1.1 Sepsis
Sepsis is life-threatening organ dysfunction caused by a dysregulated host
response to infection [1]. It is a common and important clinical problem associated with
significant morbidity and mortality, and in North America, approximately one million
cases of sepsis occur annually, leading to severe sepsis 40% of the time and 300, 000
deaths [2]. Additionally, sepsis remains the leading cause of death in intensive care units
(ICU). Sepsis also presents a significant economic burden as it consumes up to 45% of
total ICU costs in the United States, or $24 billion annually [3,4]. Morbidity and
mortality in sepsis are largely due to multiple organ dysfunction and failure, most
commonly in the pulmonary, renal, and cardiac systems [3,5,6]. Despite intensive basic
and clinical research, treatment of sepsis and related organ dysfunction consists largely of
supportive care (i.e. antibiotics and intravenous fluids [IV]), with no specific therapy
available for the treatment of systemic inflammation or resulting cellular and organ injury
[7].
Part of this dysregulated response is persistent systemic inflammation, causing
major pathophysiological changes, including increased microvascular permeability
leading to organ edema, damage, and dysfunction distant to the site of infection. Septic
organ dysfunction is characterized by the activation and dysfunction of microvascular
endothelial cells (MVEC), leading to a loss of microvascular barrier function [8]. In
addition, septic inflammation is characterized by the activation of both circulating
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(polymorphonuclear leukocyte [PMN]) and tissue-resident inflammatory cells
(macrophages), as well as the enhanced activity of soluble inflammatory mediators,
including lipopolysaccharide (LPS) and various cytokines (e.g. tumour necrosis factor
[TNF] α, interleukin [IL] 1β, interferon [IFN] γ) [8].

1.2 Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is a critical pulmonary illness
characterized by increased pulmonary vascular permeability, which ultimately leads to
severe pulmonary edema, increased lung weight, and loss of aerated lung tissue [9].
ARDS is triggered by direct pulmonary insults, such as gastric aspiration, smoke
inhalation, and pneumonia, or by indirect insults, such as sepsis, pancreatitis, and trauma
[10]. ARDS is also characterized by the activation of alveolar macrophages as well as the
influx of circulating neutrophils, resulting in the enhanced production and release of
inflammatory mediators including pro-inflammatory cytokines, oxidants, and proteases,
ultimately leading to hypoxemia and potentially, death [11]. Persistent inflammation
results in injury and dysfunction of the pulmonary microvasculature, which is
characterized by a loss of structural integrity and increase in barrier permeability [11,12].
The disruption of junctions between adjacent pulmonary MVEC (PMVEC), specifically
adherens junctions comprising vascular endothelial (VE)-cadherin, contributes to this
pathology [10]. This results in the accumulation of protein-rich edema in the interstitial
space, which ultimately crosses the injured epithelial barrier into the alveoli, impeding
proper gas exchange and oxygenation.
Despite advances in understanding ARDS, effective pharmacologic interventions
shown to improve patient outcomes remain lacking [10]. While mortality rates associated
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with ARDS have decreased recently due to improvements in mechanical ventilation and
fluid management, mortality rates remain at approximately 30% [10]. Further, surviving
patients deal with long-term pulmonary complications like persistent inflammation and
fibrosis leading to an impaired quality of life [10].

1.3 Microvascular Endothelial Cells
The inner lining of all blood vessels consists of a monolayer of endothelial cells
(EC), which serves as a selectively permeable barrier between the circulation and
surrounding tissue [13–16]. In addition to the endothelial monolayer, blood vessels are
comprised of multiple layers of smooth muscle cells, connective tissue, and pericytes
[17]. However, capillaries, which are the smallest of all blood vessels, consist only of the
single endothelial monolayer [17]. The microvasculature, includes the arterioles,
capillaries, and postcapillary venules [17].
The EC is a multifunctional cell. These functions include regulation of
angiogenesis, the maintenance of a nonthrombogenic barrier, and the modulation of
blood flow and vascular resistance. Further, EC mediate host immune responses via
release of pro- and anti-inflammatory mediators, such as cytokines and chemokines, as
well as regulation of leukocyte adhesion to the endothelial surface via changes in
expression of surface adhesion molecules [15,17,18]. However, the primary role of EC is
to act as a selectively permeable barrier between the contents of the vasculature and the
surrounding tissue. In order to control the substances passing through the semi-permeable
layer, EC have selective transport systems to target specific substrates. For example,
larger substrates are thought to pass through the endothelial barrier membrane via a
transcellular route mediated by caveolae [19].

4

1.3.1

MVEC Barrier Function
Inter-MVEC adherens and tight intercellular junctions are required for the

establishment and maintenance of MVEC barrier function [13,14,16,20–23]. However,
dynamic control of endothelial permeability, which occurs through both paracellular and
transcellular pathways, does allow for the regulated exchange of plasma proteins, solutes,
and liquid between the vasculature and surrounding tissues [13,14,16,20–23]. The
paracellular pathway consists of transport through the intercellular space between
adjacent EC, whereas the transcellular pathway, also known as transcytosis, consists of
active receptor-mediated transport through the cell itself [13,14,16,17]. Under basal
conditions, only small molecules (e.g. ions) cross the endothelial barrier through the
paracellular pathway [13,17]. Larger macromolecules are actively transported through
membrane receptor/vesicle-mediated transcytosis [13,16,17,24].

1.3.2

Regulation of MVEC Barrier Function
Interaction of adjacent EC through adherens and tight intercellular junctions is the

key mechanism regulating microvascular endothelial permeability [13,14,16,20–23].
These transmembrane junctional structures are comprised of multiple cell surface
proteins, including VE-cadherin within adherens junctions, and the claudins and
occludins within tight junctions [13,14,16,20,21,23].
In addition to inter-MVEC interaction, microvascular permeability is also thought
to be regulated by a mesh-like matrix, known as the glycocalyx, found on the luminal
surface of the endothelial monolayer [13,25]. The glycocalyx is made up of glycoproteins
and proteoglycans, including syndecans and glypicans, in addition to glycosaminoglycans
(GAGs) [13,17,25]. Interestingly, the ability of the glycocalyx to facilitate maintenance

5

of a semi-permeable barrier to fluid and proteins may not occur in all microvascular beds
(i.e. pulmonary microvasculature) as degradation of the glycocalyx was not associated
with increased albumin flux or edema within the lung [26]. The glycocalyx is also
involved in the regulation of circulating leukocyte-MVEC interactions such as transMVEC migration [13,25].
The extracellular matrix (ECM) is also known to be a structural component
required for the maintenance of endothelial barrier integrity. EC bound to the ECM are
generally quiescent, as activation of integrins on the basolateral surface of EC following
binding to the ECM generates signals that stabilize adjacent cell-cell and cell-ECM
adhesions, which are vital to the formation and preservation of an endothelial barrier
[27]. Thus, both the glycocalyx and the ECM are critical to establishing and maintaining
endothelial integrity and barrier function.

1.4 MVEC Dysfunction
Dysfunction of the microvasculature under conditions of inflammation or
infection is central to the resulting organ injury, dysfunction, and failure. This
microvascular dysfunction is primarily characterized by activation and dysfunction of
MVEC, leading to a loss of microvascular barrier function as well as upregulation of cell
surface leukocyte receptors and upregulation of pro-thrombotic pathways
[13,14,20,21,28,29]. Importantly, this dysfunction results in increased tissue
inflammation and edema due to enhanced adhesion and diapedesis of leukocytes as well
as increased microvascular permeability, both of which can lead to organ dysfunction and
failure [13,14,20,21,28,29].
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EC dysfunction occurs under many different conditions, including but not limited
to local tissue injury, infection, and sepsis, but is also a hallmark of vascular diseases
such as atherosclerosis. Within the setting of injury and/or infection, MVEC dysfunction
is initiated by the interaction of MVEC with circulating blood components, including
PMNs and soluble inflammatory mediators (e.g. bacterial products like LPS, or cytokines
like TNF). In fact, MVEC dysfunction following injury or infection is highly PMNdependent [8,30–33]. There are several mechanisms of PMN-dependent cell/tissue injury.
These include physical interaction (e.g. PMN-MVEC adhesion), release of reactive
oxygen species (ROS), proteases/peptides (e.g. metalloproteinases), pro-inflammatory
cytokines/chemokines, and cytotoxic neutrophil extracellular traps (NETs) [33,34].

1.4.1

Features of MVEC Dysfunction
The primary features of MVEC dysfunction are the loss of MVEC barrier

function and the increased PMN-MVEC interaction. The loss of MVEC barrier function
is mediated through several mechanisms, including but not limited to disassembly of
inter-MVEC adherens and tight junctions due to cleavage or modification of membrane
junctional proteins; gap formation due to actin cytoskeleton rearrangement and
microtubule-dependent MVEC contraction; activation of trans-MVEC transport systems;
and MVEC death [21,22,35]. Enhanced PMN-MVEC interaction is associated with
increased PMN recruitment out of the vasculature into tissues, and is thought to be
dependent on a number of factors, including but not limited to increased release of proinflammatory cytokines and chemokines, upregulation of MVEC cell surface leukocyte
receptors, and shedding of the glycocalyx [36,37].
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1.4.2

Mechanisms of MVEC Barrier Dysfunction

MVEC activation by inflammatory cytokines and leukocytes leads to increased
MVEC permeability, and this increased permeability is primarily due to loss of interMVEC junctions and MVEC retraction [13,14,20,21,28,29]. As VE-cadherin is critical to
the formation of MVEC adherens junctions, modifications of its structure along with its
associated intracellular catenins, including p120, - and -catenin, significantly
attenuates barrier integrity [13,14,16,20,21,23,38]. For example, enhanced barrier
permeability is correlated with tyrosine phosphorylation of the VE-cadherin/catenin
complex [13,14,16,39].
Activation of MVEC by pro-inflammatory cytokines (e.g. TNFα) has also been
shown to induce loss of barrier function by promoting cleavage of VE-cadherin and the
generation of a soluble extracellular fragment [13,16,40,41]. This VE-cadherin cleavage
appears to be at least partially dependent on tyrosine phosphorylation of the VEcadherin/catenin complex by several kinases (i.e. Protein Kinase C [PKC] and p38
mitogen-activated protein kinase) [13,16,40,41]. Finally, thrombin has been found to bind
protease-activated receptor (PAR) 1 on the MVEC surface, and promote barrier
dysfunction by increasing cytosolic Ca2+ concentrations leading to PKCα-dependent VEcadherin phosphorylation and subsequent internalization [13,16,42]. Collectively, these
studies illustrate the complex intercellular signaling pathways that are involved in the
control of MVEC barrier function, and that are often disrupted under pathological
conditions, such as tissue injury or infection.
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1.5 Metalloproteinases
Metalloproteinases are a diverse group of endopeptidases comprised of many
distinct families [43]. Matrix metalloproteinases (MMPs) and the closely related a
disintegrin and metalloproteinases (ADAMs) share several common structural domains,
including a signal peptide, the pro-peptide domain, and the catalytic domain [44]. The
pro-peptide domain contains a cysteine residue that ligates the active site zinc (Zn2+) or
Ca2+ and maintains the enzyme in an inactive conformation until this interaction is
disrupted. MMPs are generally categorized by their domain structure [45,46]. In addition
to the domains common to all MMPs and other metalloproteinases (i.e. signal peptide,
pro-domain, and catalytic domain), specific subsets of MMPs contain unique domains.
Many MMPs contain a hemopexin-like C-terminal region, which is connected to the
catalytic region by a short flexible hinge and can mediate protein-protein interactions (i.e.
binding to tissue inhibitor of metalloproteinases [TIMPs]). Additionally, the membrane
type (MT)-MMPs contain a furin-recognition domain allowing for activation by the proprotein convertase furin, as well as a C-terminal transmembrane domain [46–48].
ADAMs also contain a furin cleavage site as well as a disintegrin-binding domain, which
can interact with integrins and mediate cell-ECM interactions [44].
Metalloproteinases are regulated in four ways – gene expression,
compartmentalization, pro-enzyme activation, and enzyme inactivation [46].
Metalloproteinase expression can be mediated by many factors, such as growth factors
(e.g. transforming growth factor [TGF] β and vascular endothelial growth factor
[VEGF]), cytokines (e.g. IFNγ, IL1β, and IL6), cell-ECM signaling through integrins,
and pathogen-associated molecular patterns (PAMPs) [44,49,50].
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Studies have shown that metalloproteinases demonstrate considerable overlap in
their substrate selectivity in vitro. Thus, regulation of metalloproteinase activity is critical
and likely occurs at multiple levels. Compartmentalization (e.g. the pericellular
accumulation of metalloproteinases in specific microenvironments through cell-enzyme
interactions) is thought to be important in regulating extracellular substrate degradation
[44,46,50]. Additionally, while many metalloproteinases are secreted in their active form,
some (i.e. specific MMPs) are secreted as zymogens, or inactive precursors, and remain
in this inactive conformation due to the interaction between the pro-peptide and catalytic
domains [47]. Disruption of this interaction, which occurs through multiple mechanisms
including proteolytic removal or oxidation of the pro-domain, allows for MMP activity
[46,47,49,51]. Finally, metalloproteinase activity is directly inhibited by specific
inhibitors, the TIMPs [49,52].
Multiple MMPs are expressed by MVEC, some of which are localized to vesicles
likely for rapid secretion following activation. While data on metalloproteinase regulated
MVEC dysfunction is limited, changes in metalloproteinase expression in response to
proinflammatory cytokines has been characterized in other types of EC. For example,
angiotensin (ANG) II treatment of human umbilical vein endothelial cells (HUVEC)
stimulates TNF production that leads to enhanced MMP2 production and release, and
co-treatment with anti-TNF antibodies blocks this increased MMP2 production [53].
Interestingly, stimulation of brain EC with TNF and IL1, selectively upregulates
MMP9 production, but does not alter MMP2 expression [54]. This suggests vascular bed
specificity in MMP expression in response to cytokines. ADAM expression is also
mediated by cytokines. Specifically, ADAM17 expression by murine brain EC is strongly
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upregulated by many pro-inflammatory cytokines (i.e. TNF, IL-1, IFN) and growth
factors (epithelial growth factor [EGF], VEGF) [55].
EC, including MVEC, also express and release higher levels of metalloproteinases
following infection. For example, LPS, a component of the outer membrane of gram
negative bacteria, elicits strong increases in the expression and activity of ADAM10 and
ADAM17 in human PMVEC [56]. Further, Japanese encephalitis virus, a single stranded
ribonucleic acid (RNA) virus, increases expression of MMP9 in human brain MVEC
[57]. Additionally, infection of HUVEC with Chlamydophila pneumoniae, a bacteria
associated with lung infections such as pneumonia, leads to increased MMP9 production
while infection of HUVEC with Dengue virus leads to overproduction of MMP2 and to a
lesser extent of MMP9 [57–59]. Finally, while it has yet to be linked to EC-specific
expression, humans with severe sepsis have significantly elevated plasma MMP2, -3, -7, 8, and -9 [60]. It is important to note, however, that at least part of the EC
metalloproteinase response to infection may be mediated through autocrine signaling by
cytokines expressed by EC in response to the infection.

1.5.1

Role of Metalloproteinases in Endothelial Dysfunction

Multiple MMPs and ADAMs have been shown to cleave inter-MVEC junctional
proteins, and thereby mediate microvascular dysfunction through increased vascular
permeability [42,56,61–63]. For instance, MMP7, ADAM10, and -12 are all capable of
cleaving VE-cadherin, the integral cell surface transmembrane protein of endothelial
adherens junctions [42,62]. Further, increased MMP2 and -9 expression following
HUVEC infection by Dengue virus is correlated with a loss of expression of VE-cadherin
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cell-cell adhesion suggesting that MMP2 and -9 may also be capable of cleaving VEcadherin [59].
MMP2 and -9 along with ADAM17 are also capable of cleaving tight junction
associated proteins such as occludin, zona occludens (ZO) 1, and junctional adhesion
molecules (JAMs) [56,61,63]. In addition to cleavage, tyrosine phosphorylationdependent disassembly of crucial adhesive junctional proteins may also be MMP
dependent, as permeability induced by tyrosine phosphatase inhibitors have been shown
to be blocked by MMP inhibitors [41,64]. Moreover, knockdown of ADAM10 following
small interfering RNA (siRNA) treatment of either EC or activated leukocytes stabilizes
the microvascular barrier as well as reduces leukocyte transendothelial migration [42].
Collectively, these studies suggest increased metalloproteinase expression and activity
promotes MVEC dysfunction through the cleavage and/or disruption of critical interMVEC junctional proteins.
MMPs and ADAMs with thrombospondin motifs (ADAMTSs) have also been
found to cleave the ECM surrounding the vasculature, which can modify EC function
through disrupted endothelial-ECM interactions, ultimately leading to increased vascular
permeability [65–70]. For example, proteolytic degradation of ECM constituents,
including fibronectin, laminin, and type IV and V collagens, by MMPs, including MMP2
and -9, results in increased permeability across EC monolayers in vitro as well as
increased pulmonary edema in vivo [69,70]. The cleavage and degradation of other ECM
protein constituents, including hyaluronan and aggrecan, have also been shown to
augment endothelial permeability [70,71]. Additionally, MMP9 has been shown to be
responsible for the cleavage and release of VEGF bound to the ECM, which results in
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increased microvascular permeability through internalization of VE-cadherin [72]. Thus,
these studies suggest increased metalloproteinase activity drives MVEC dysfunction
through the proteolytic processing of integral MVEC structural determinants (i.e. the
ECM) resulting in MVEC barrier dysfunction and enhanced microvascular leak.
Supportive evidence for the role of metalloproteinases in microvascular and MVEC
dysfunction includes data from several studies using synthetic metalloproteinase
inhibitors, such as GM6001. For example, stimulating HUVEC with TNF increases
metalloproteinase expression and activity, and treatment of these HUVEC with GM6001
reduces the TNF-induced increase in MVEC permeability through inhibition of VEcadherin cleavage [41,42]. Additionally, in models of brain edema due to dysfunction of
the blood-brain barrier, treatment of murine cerebrovascular EC with GM6001 leads to
decreased microvascular leak due to the stabilization of tight junction adhesive proteins
and decreased EC F-actin stress fiber formation through the inhibition of MMP9 [73,74].
Collectively, these studies highlight the potential role of metalloproteinase inhibition in
the control of MVEC barrier dysfunction.
In addition to controlling MVEC barrier dysfunction, metalloproteinases are also
involved in mediating PMN-MVEC interaction through multiple potential mechanisms.
Specifically, metalloproteinases, including both MMPs and ADAMs, can mediate PMNMVEC interaction through shedding of leukocyte receptors, such as intercellular
adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), from the
MVEC surface. For example, MMP14, as well as ADAM10 and -17 have been found to
cleave ICAM1 [75–77]. Further, the interaction between ICAM1 and MMP14 appears to
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be mediated by interaction between the cytoplasmic domains [77]. Additionally,
ADAM17 has been shown to cleave VCAM1 from the surface of heart and aorta EC
following stimulation with phorbol 12-myristate 13-acetate (PMA) [78]. Cleavage of
ICAM1 and VCAM1 by MMPs and ADAMs reduces MVEC surface expression of
ICAM1 and VCAM1 leading to decreased PMN-MVEC interaction [78]. These studies
suggest that MMPs and ADAMs have the ability to downregulate PMN-MVEC
interactions, reduce inflammation, and could also be involved in the resolution of
inflammation.
Metalloproteinases have also been proposed to have a role in regulation of PMNMVEC interaction through cleavage of the glycocalyx. While degradation of the
glycocalyx is thought to be primarily mediated by heparanase, glycocalyx degradation
still occurs in mice lacking heparanase, and this degradation is associated with increased
MMP activity [16,37]. Collectively, this potential degradation of the glycocalyx could
lead to increased PMN-MVEC interaction; however, this remains to be confirmed. Thus,
the role of metalloproteinases, including both MMPs and ADAMs, in MVEC dysfunction
is complex, including promoting the loss of MVEC barrier function and increased
leukocyte recruitment through degradation of the glycocalyx, while also decreasing direct
leukocyte-MVEC interaction. Further, the specific roles likely depend on the
metalloproteinase in question, the specific vascular bed, and the type of inflammation or
injury.

1.6 Tissue Inhibitor of Metalloproteinases (TIMPs)
The TIMP family is comprised of four members, TIMP1-4, in humans and other
mammals (e.g. mice, rats) [52,79]. TIMPs inhibit active metalloproteinases in a 1:1
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stoichiometric inhibitor-to-enzyme ratio [52,79]. Specifically, the N-terminal domain of
TIMP molecules interacts with the active site of metalloproteinases in a fashion similar to
metalloproteinase substrates, resulting in inhibition of catalytic activity [52,79].
TIMP expression varies in the different vascular beds throughout the body,
including both micro- and macrovascular beds; however, all TIMP family members are
expressed within at least one vascular bed, supporting the importance of TIMPs to EC
function. For example, TIMP1, -3, and -4 are expressed by brain MVEC, and TIMP1, -2,
and -3 are expressed by EC isolated from the aorta, iliac artery, and coronary artery [80–
82]. Additionally, TIMP3 is expressed by pulmonary MVEC, whereas TIMP2 and -4 do
not appear to be [83,84].
Besides EC, TIMPs are also often expressed by multiple other cells associated with
the vasculature. For example, TIMP3 is expressed by pericytes, and TIMP2 and -4 are
expressed by vascular smooth muscle cells [85–87]. Importantly, TIMPs expressed by
these adjacent cell populations are localized within the microenvironment surrounding
the MVEC, and in many instances, have been found to be involved in regulation of
MVEC function [85–88]. Additionally, while TIMP1, -2, and -4 are secreted and thus
function in a soluble manner, TIMP3 is known to be bound to sulfated GAGs located in
the ECM [52,79,89].
Within the setting of tissue injury and infection, the expression of the various
TIMPs appears to be differentially regulated (i.e. expression of different TIMPs does not
change in the same direction) [53,80,81,83,87,88,90,91]. For example, treatment of brain
MVEC with pro-inflammatory cytokines, specifically IL1β and TNFα, led to an increase
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in Timp1 and a decrease in Timp3 messenger ribonucleic acid (mRNA) expression [80].
Additionally, stimulation of brain MVEC with homocysteine, which is associated with
endothelial dysfunction, increased TIMP1 expression but decreased TIMP4 expression
[81].
Interestingly, the TIMP expression in response to various stimuli also appears to be
cell-dependent as stimulation of a transformed brain EC line (hCMEC/D3) with TNFα
resulted in increased TIMP3 expression [92]. There is, however, some evidence
suggesting that similar expression patterns for TIMPs may also be observed across
different vascular beds. For example, while it has yet to be linked to MVEC-specific
expression, TIMP1, -2, and -4 levels in plasma are significantly elevated in patients with
severe sepsis [60,93,94]. Further, brain MVEC treated with homocysteine have increased
TIMP1 protein expression [81]. Conversely, similar to the reduction in Timp3 expression
in brain MVEC under inflammatory conditions, TIMP3 expression (mRNA and protein)
was significantly decreased in pulmonary MVEC following treatment with IFN, IL1β,
and TNFα [83].

1.6.1

Metalloproteinase-Dependent TIMP Functions

In general, all four TIMPs have been shown to collectively inhibit all MMPs in
vitro [95,96]. There are, however, some differences between TIMPs. For example,
TIMP1 does not appear to be able to regulate MT-MMPs [47,50]. In addition, ADAMs
and ADAMTSs appear to be primarily inhibited by TIMP3 [47]. Some TIMPs have also
been found to form a complex between an active MMP and latent pro-MMP leading to
activation of the latent MMP. This has been demonstrated extensively with TIMP2,
which binds active MMP14 and latent MMP2, and facilitates MMP2 activation [96].
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The majority of our understanding of metalloproteinase and TIMP interactions
arises from in vitro studies utilizing purified proteins [95]. Hence, much of this data
reveals the potential for metalloproteinase-TIMP interaction but does not provide
information as to physiological relevance. There have been a number of in vivo studies
using mice lacking specific TIMPs that have sought to identify physiological interactions.
For example, TIMP1 has been found to interact with and inhibit MMP7 (also referred to
as matrilysin) as MMP7 activity was increased in the airway epithelium of mice lacking
TIMP1 following napthalene exposure [97]. Further, co-immunoprecipitation
demonstrated that TIMP1 directly binds to MMP7 [97].
Use of different models of injury and inflammation with mice lacking TIMP3 have
found that TIMP3 is the physiological inhibitor of ADAM17 [95]. Specifically,
inflammation is generally increased in mice genetically lacking TIMP3 following
multiple models of injury (i.e. partial hepatectomy, bleomycin-induced lung injury), and
in most cases, this increased inflammation is associated with increased TNFα shedding
resulting from augmented ADAM17 activity [98]. TIMP3 has also been associated with
multiple other metalloproteinases in vivo, primarily through the observation of increased
metalloproteinase activity (e.g. MMP9) or increased substrate degradation (e.g. aggrecan
cleavage potentially by ADAMTS5) in mice lacking TIMP3 [95,99].
Rescue of the basal and pathological phenotypes in mice lacking specific TIMPs
with small molecule metalloproteinase inhibitors also provides further support for the
metalloproteinase dependent roles for TIMPs in vivo [83,98–101]. Thus, through
regulation of metalloproteinase activity, TIMPs are able to finely tune processing of a
wide variety of extracellular substrates ranging from degradation of the ECM to cleavage
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of cytokines and cytokine receptors from the cell surface, which suggests TIMPs are
critical for the regulation of many cellular functions from cell-cell interaction to influx of
leukocytes into injured tissues.

1.6.2

Role of TIMPs in Endothelial Function

A number of studies have characterized TIMP expression within multiple EC types
under various conditions; however, the direct evidence of a role for EC-derived TIMPs in
endothelial function is more limited. Indirect evidence from mice globally deficient for
individual TIMPs as well as from studies of recombinant TIMPs suggests that TIMPs
play an integral role in the setting of inflammation, as well as potentially in the setting of
endothelial dysfunction following tissue injury. For example, TIMP1-3 all appear to
support the blood brain barrier (BBB) following injury, although the mechanism may
differ between TIMPs. Mice lacking TIMP1 have increased ischemic injury and bloodbrain barrier disruption compared to wild type (WT) mice following focal cerebral
ischemia and this is associated with increased MMP9 secretion and activity [94]. Further,
increased expression of TIMP1 in brain EC treated with ANG (1-7) following hypoxiainduced injury was responsible for restoration of tight junctions and reduced EC
permeability [102].
TIMP3 appears to regulate EC barrier function through metalloproteinasedependent mechanisms. Timp3-/- mice have augmented leak of Evans blue (EB)-labeled
albumin into their snout and kidneys at baseline, which is thought to be due to the
absence of TIMP3 in pericytes, resulting in enhanced microvascular permeability due to
increased global metalloproteinase activity [68]. Timp3-/- mice also have increased
pulmonary EB-albumin leak at baseline, which is likely due to loss of PMVEC-derived
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TIMP3 as PMVEC from Timp3-/- mice also exhibit impaired barrier function in vitro
compared to PMVEC from WT mice [83]. Further, treatment of Timp3-/- PMVEC with
global metalloproteinase inhibitor GM6001 appears to restore basal PMVEC barrier
function [83]. Together, these studies suggest that TIMP3 may be an important
homeostatic regulator of EC function in healthy tissue, such as establishing a selectively
permeable barrier, and that this role for TIMP3 is at least partly dependent on the ability
of TIMP3 to inhibit metalloproteinases [70,83].
While the classic function for TIMPs is inhibition of metalloproteinase activity,
there are multiple lines of evidence suggesting that TIMPs may regulate EC function
through metalloproteinase-independent mechanisms. Specifically, mice lacking TIMP2
exhibit blood-brain barrier disruption compared to WT mice following focal cerebral
ischemia; however, no changes were observed in MMP activity [94]. Additionally,
injection of recombinant TIMP3 (rTIMP3) led to decreased vascular leak across the
blood-brain barrier in a model of traumatic brain injury, but this effect was not mimicked
by use of a synthetic metalloproteinase inhibitor [103].
TIMP2 and -3 have also been found to inhibit VEGF signaling through
metalloproteinase-independent mechanisms [90,91,104]. For TIMP3, this inhibition
occurs through TIMP3 binding to the VEGF receptor (VEGFR) and blocking VEGFVEGFR2 interaction, ultimately inhibiting angiogenesis [90,91]. During angiogenesis,
VEGF acts as a potent mediator of increased endothelial permeability through
phosphorylation and internalization of VE-cadherin and subsequent disassembly of cellcell adhesive contacts [13,90,91,105]. Importantly, both TIMP2 and -3 have been found
to inhibit angiogenesis, including inhibition of both EC proliferation and migration,
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through inhibition of VEGF signaling [90,91,106]. Thus, these studies together suggest
that TIMP2 and -3 may promote brain EC barrier function through metalloproteinaseindependent mechanisms.
In addition to regulation of MVEC barrier function, TIMPs have also been
associated with regulation of PMN-MVEC interaction. Specifically, TIMP3 has been
found to inhibit shedding of VCAM1 from the surface of aortic EC following treatment
with IL1β, TNFα, or the phorbol ester PMA [106]. Specifically, aortic EC from Timp3-/mice had increased VCAM1 shedding compared to aortic EC from WT mice, and this
inhibition of VCAM1 shedding by TIMP3 was likely through inhibition of ADAM17 as
knockdown of ADAM17 protected against increased VCAM1 shedding [106]. Thus,
TIMPs appear to be critical regulators of MVEC dysfunction following tissue
injury/infection, including protection against loss of MVEC barrier function through
metalloproteinase-dependent and -independent mechanisms, as well as the regulation of
leukocyte recruitment by stabilization of leukocyte receptors on the MVEC surface.

1.7 Rationale
Pathophysiological changes in the microvasculature are important mechanisms of
sepsis-induced organ dysfunction and mortality. Specifically, increased pulmonary
microvascular permeability during sepsis-induced ARDS, which is due to PMVEC
injury, dysfunction and death, is the primary cause of the protein-rich edema fluid that
accumulates within the damaged lung tissue [13,14,20–22,29,104]. While many
mechanisms contributing to septic PMVEC injury/dysfunction have been described
[13,14,20–22,28,29,104,107], no treatment for the septic tissue damage and organ
dysfunction has been identified. Moreover, endogenous mechanisms protecting against

20

sepsis-induced PMVEC dysfunction are poorly characterized. Metalloproteinases are
capable of processing many extracellular proteins, including inter-MVEC junctional
proteins (i.e. VE-cadherin, JAM-A), and thereby disrupting MVEC barrier function and
increasing microvascular permeability (Figure 1-1). TIMPs inhibit metalloproteinase
activity, and thereby are critical to maintaining MVEC barrier function and restricting
PMN-MVEC interaction. While recent studies support a role for metalloproteinases and
TIMPs in mediating MVEC barrier dysfunction, many of these studies used in vitro
models with HUVEC. Importantly, EC from the micro- and macrovasculature have
different biological properties and thus, examining the role of metalloproteinases and
TIMPs in the microvasculature, specifically in PMVEC, is critical [108,109]. Further, the
potential role of the balance between metalloproteinases and TIMPs in regulating
PMVEC barrier dysfunction as well as other aspects of PMVEC activation (i.e. leukocyte
interactions) have not been examined under septic conditions.

1.8 Objectives
I propose to:
1. Characterize PMVEC expression of metalloproteinases and TIMPs under
control and septic conditions in vitro and ex vivo.
2. Examine the role of the metalloproteinase/TIMP balance in PMVEC
activation and dysfunction during sepsis in vitro.
For this, I will examine PMVEC metalloproteinase and TIMP expression in WT
PMVEC under homeostatic and septic conditions, as well as under conditions in which
the metalloproteinase/TIMP balance has been disrupted (i.e. Timp3-/- PMVEC). To
examine the role of the metalloproteinase/TIMP balance in PMVEC activation and
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Figure 1-1: Disruption in the balance between metalloproteinases and tissue
inhibitors of metalloproteinases (TIMPs) leading to increased metalloproteinase
activity promotes microvascular endothelial cell (MVEC) activation and dysfunction
following tissue injury or infection. (A) Cleavage of inter-MVEC junctional proteins
(i.e. vascular endothelial [VE]-cadherin, junctional adhesion molecule [JAM]-A reduces
MVEC barrier function and increases permeability for larger macromolecules. (B)
Shedding of leukocyte receptors reduces polymorphonuclear leukocyte (PMN) adhesion
to endothelial cells in an attempt to reduce increased PMN migration into the surrounding
tissue. (C) Cleavage of the extracellular matrix/glycocalyx increases MVEC permeability
and promotes PMN-MVEC interaction. Importantly, TIMPs inhibit metalloproteinase
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activity, and thereby are critical to maintaining MVEC barrier function and restricting
PMN-MVEC interaction.
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dysfunction, I will utilize two complementary approaches: 1) PMVEC treated with
synthetic metalloproteinase inhibitors, and 2) PMVEC from Timp3-/- mice.

1.9 Hypothesis
I hypothesize that septic murine PMVEC barrier dysfunction contributes to
disruption of the balance between metalloproteinases and TIMPs leading to increased
metalloproteinase activity.
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Chapter 2

2

Methodology

2.1 Pulmonary Microvascular Endothelial Cell (PMVEC)
Isolation for in vitro Analysis
To study the function of the metalloproteinase/TIMP balance in maintaining
pulmonary microvascular barrier function following septic lung injury, murine PMVEC
were isolated from the lungs of healthy male WT and Timp3-/- mice and cultured for use
in all in vitro experiments, as previously described [110,111]. In brief, following lung
isolation, lung tissue was finely minced and digested using 0.3% collagenase in Hank’s
Balanced Salt Solution (HBSS, #14170-112, Invitrogen). Following filtration through a
100 μm pore mesh sieve, cells were incubated with magnetic microbeads (Dynabeads M450 sheep anti-rat IgG, #11035, Dynal Biotech Inc., Lake Success, NY), coupled to antiplatelet endothelial cell adhesion molecule (PECAM; CD31) antibodies (Rat anti-mouse
CD31 monoclonal antibody, #557355, BD Pharmingen, Franklin Lakes, NJ). Microbeadbound PMVEC were magnetically captured (MPC magnet, Dynal Biotech Inc., Lake
Success, NY) and subsequently washed and suspended in growth medium (Dulbecco’s
modified Eagle’s medium [DMEM] supplemented with 20% heat inactivated fetal bovine
serum [FBS], #11885-092, Invitrogen, Carlsbad, CA; 1% Penicillin/Streptomycin [10
000 U/mL], #15140122, Invitrogen; 2% [4-2[2-hydroxyetyl]-1-piperazineethanesulfonic
acid] [HEPES] buffer [1M], #15630-080, Invitrogen), then seeded into a 1% gelatincoated cell culture flask and incubated at 37°C with 5% carbon dioxide (CO2). Cells were
assessed weekly to ensure appropriate morphology and once approximately 90%
confluent, cells were stained with fluorescent acetylated-low density lipoprotein (LDL)
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(Biomedical Technologies, # BT902, Stoughton, MA) and assessed by
immunofluorescence, as well as stained with fluorescently-labelled antibodies against
endothelial cell markers (i.e. CD31, CD34, CD146 and CD202) and assessed by flow
cytometry to ensure purity. Collectively, these processes result in 99% PMVEC culture
homogeneity. PMVEC were then grown in supplemented DMEM growth medium and
incubated at 37°C with 5% CO2 until the cell monolayer reached confluence. PMVEC at
passages 5-12 were used for all experiments

2.2 PMVEC Isolation from Healthy and Septic Mice for ex
vivo Analysis
To further examine the role of the metalloproteinase/TIMP balance in sepsis,
PMVEC were isolated from healthy (naïve and sham surgery) and septic (cecal ligation
and perforation [CLP] model of sepsis) mice. For these studies, male WT and Timp3-/mice (8-12 weeks) were randomized to control (naïve and sham surgery) or volumeresuscitated CLP-sepsis for 1, 2, or 4h, as previously described [8,83]. Importantly, naïve
mice exhibited no difference in gene expression compared to 4h sham mice, and thus
were used in subsequent studies (Figure 2-1). PMVEC were isolated using the Mouse
Lung Dissociation Kit (#130-095-927, Miltenyi) as per the manufacturer instructions.
Briefly, the pulmonary vasculature was flushed with 10 mL saline and the lungs isolated.
Lungs were then physically disrupted using the gentleMACSTM Dissociator (Miltenyi)
followed by chemical digestion via Collagenase D and DNAse A (#130-095-927,
Miltenyi) for 30 min at 37°C. The whole lung disgest was strained through 100 μm and
70 µm cell strainers (#10199-658, VWR; #130-098-462, Miltenyi; respectively) and
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Figure 2-1: Pulmonary MVEC (PMVEC) from sham mice exhibit no significant
differences in gene expression compared to PMVEC from naïve mice. Timp and
metalloproteinase mRNA expression are nearly identical, justifying the decision to use
naïve mice instead of 4h sham mice for subsequent PMVEC endothelial cell isolation
(n=4-8).
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resuspended in DMEM supplemented with 0.5% bovine serum albumin (BSA) and 0.5M
EDTA (pH 8.0). Once isolated, the whole lung cell suspension was incubated with CD45
mouse MicroBeads (#130-097-153, Miltenyi) for 15 min at 4°C and then CD45+ cells
were magnetically separated using LS columns (#130-042-401, Miltenyi). The CD45cells were then incubated with CD31 mouse MicroBeads (#130-097-418, Miltenyi) for 15
min at 4°C and the CD45-/CD31+ cells magnetically isolated using new LS columns.
These cells were spun at 300 g for 5 min at 4°C, resuspended in phosphate buffered
saline (PBS) with RNAse inhibitor (4U/ul, #129916, Qiagen), and placed at -80°C for
storage. As above, purity of the isolated CD45-/CD31+ cells was confirmed by flow
cytometry using fluorescently-labelled antibodies against endothelial cell markers (i.e.
CD31, CD34, CD146 and CD202; Figure 2-2).

2.3 Assessment of PMVEC Expression of Timp1-4,
Metalloproteinases and Cell Adhesion Molecule
Messenger Ribonucleic Acid (mRNA)
PMVEC Timp1, -2, -3, -4, Mmp2, -7, -9, Adam10, -17, Icam1, Vcam1, and Eselectin (Sele) mRNA expression levels were examined in male WT and Timp3-/PMVEC in vitro, and in male WT and Timp3-/- PMVEC ex vivo by quantitative real-time
polymerase chain reaction (qRT-PCR). For in vitro analysis, cells were cultured in 6-well
cell culture plates coated with 1% gelatin. Once confluent, PMVEC were treated for 1, 2,
and 4h with PBS (vehicle control), cytomix (an equimolar solution of TNFα, IL1β, and
IFNγ, 30 ng/mL, PeproTech, Rocky Hill, NJ), LPS (10 μg/mL, 0111:B4 serotype,
#L2630, Sigma) or a combination of both cytomix and LPS (30 ng/mL, 10 μg/mL,
respectively), used to mimic septic conditions. Following stimulation, cells were lysed
and RNA isolated using the RNeasy Mini Kit following the manufactures directions
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Figure 2-2: CD45 and CD31 MicroBeads assist in selecting for a pure endothelial
cell population. Compared to whole lung single cell suspension, CD31+-selected
endothelial cells represent a purer population of endothelial cells, illustrated by the shift
in fluorescence of CD31, CD34, CD146 and CD202 staining. CD45+-depleted/CD31+selected endothelial cells represent an even purer population, compared to both whole
lung single cell suspension and CD31+-selected endothelial cells.
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(#74104, Qiagen, Hilden, Germany). Briefly, 200 μL RLT buffer containing 2 μL betamercaptoethanol was added to each well. Wells were then scraped, and cell lysate
collected and placed in Qiashredder tubes (#79656, Qiagen). Samples were spun at 14
000 x g for 2 min. Flow through was collected from the Qiashredder tubes, placed into
RNeasy spin columns, washed with a series of buffers, and the RNA eluted from the
columns by water.
For ex vivo analysis, RNA was isolated using the RNeasy Micro Kit (#74004,
Qiagen, Hilden, Germany) from PMVEC isolated from naïve, sham, and septic mice as
described in section 2.2. Briefly, cells were spun at 14 000 x g for 2 minutes and
subsequently run through a genomic column for 1 minute at 10 000 x g.
Flow through was collected and washed, and the RNA eluted from the columns.
For all isolated RNA, purity (260/230 and 260/280 ratios) and concentration was
determined by analysis with the NanoDrop 1000 spectrophotometer (Thermo Scientific,
Waltham, MA). Isolated RNA (2 μg) was reverse transcribed using a high capacity
cDNA reverse transcription kit (#4368814, Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions.
Gene expression was assessed using TaqMan Gene Expression Assays from
Applied Biosystems (Timp1: Mm00441818_m1; Timp2: Mm00441825_m1; Timp3:
Mm00441826_m1; Timp4: Mm01184417_m1; Mmp2: Mm00439498_m1; Mmp7:
Mm00487724_m1; Mmp9: Mm00442991_m1; Adam10: Mm00545742_m1; Adam17:
Mm00456428_m1; Icam1: Mm00516023_m1; Vcam1: Mm01320970_m1; Sele:
Mm01310197_m1, Invitrogen) and the CFX96 Real Time System (BioRad Laboratories
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Inc., Hercules, CA). Hypoxanthine-guanine phosphoribosyltransferase (Hprt), a
housekeeping gene, was used to normalize expression of genes of interest
(Mm00446968_m1, Invitrogen). qRT-PCR generated the cycle threshold (Ct) value for
each gene and this value was then used to determine gene expression relative to control
PMVEC (PBS-treated or isolated from naïve/sham mice). ΔCt was the normalization of
the gene of interest (i.e. Timp3) to the housekeeping gene (Hprt) within a specific sample
(i.e. 2h cytomix-treated PMVEC). ΔΔCt was the normalization of a specific sample (i.e.
2h cytomix-treated PMVEC) to the control sample (PBS-treated PMVEC). Finally, the
relative quantity (RQ) was the fold change in expression of a specific sample (i.e. 2h
cytomix-treated PMVEC) relative to the control sample (PBS-treated PMVEC). RQ was
determined by the following equation: RQ = 2-ΔΔCt.

2.4 Assessment of PMVEC Metalloproteinase Activity
Male WT and Timp3-/- PMVEC were grown to confluence in 6-well cell culture
plates coated with 1% gelatin, and treated for 4h with PBS (vehicle control), cytomix (30
ng/mL), LPS (10 μg/mL), or a combination of both cytomix and LPS (30 ng/mL and 10
μg/mL, respectively). Following stimulation, the conditioned media was collected and
placed at -80°C for storage. Cells were rinsed with PBS and then lysed by directly adding
lysis buffer (1X CellLytic extraction buffer [#C2978-50ML, Sigma-Aldrich] into each of
the wells. Cells were then placed on ice for 20 min, after which, the cell lysate was
collected using cell scrapers and placed at -80°C storage.
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2.4.1

Assessment of Global Metalloproteinase Activity
Global metalloproteinase activity in the conditioned media and cell lysate was

analyzed using the P126 OmniMMP fluorogenic substrate as per the manufacturer
instructions (BML-P126-0001, Enzo Life Sciences). Briefly, 85 μL of conditioned media
or 25 μL of cell lysate from each sample was added to each well of a clear bottom 96well black microplate (#82050-754, VWR). Fluorescently-labelled P126 substrate and
assay buffer were then added to each well, including positive controls. Wells containing
the reference peptide, P127 (BML-P127-0001, Enzo Life Sciences), were used as positive
controls and wells containing sample and assay buffer but no P126 substrate were used as
negative controls for background fluorescence. Additionally, to confirm that any
observed increase in fluorescence was due to metalloproteinase activity, GM6001 and
BB94 were added to a subset of wells. Fluorescence was measured (Excitation peak
wavelength: 328 nm [320-340 nm]; Emission peak wavelength: 393 nm [393-405 nm])
using a Victor3 multilabel fluorescence microplate reader (Wallac) at 0, 3, 5, 7, 10, 20,
and 30 min, and 1, 2, 3, 4, 5, 21 and 24h. The plate was incubated at 37°C with 5% CO2
between readings.

2.4.2

Assessment of A Disintegrin and Metalloproteinase (ADAM)
17 Specific Activity
ADAM17 activity was assessed in the cell lysate using the Sensolyte 520 Adam17

Activity Assay Kit as per the manufacturer instructions (#AS-72085, AnaSpec). Briefly,
25 μL of cell lysate from each sample was added to each well of a clear bottom 96-well
black microplate (VWR). Fluorescently-labelled substrate and assay buffer were added to
each sample, along with positive and negative controls. Wells containing purified
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ADAM17 peptide were used as positive controls and wells containing the substrate and
assay buffer but no sample were used as negative controls for background fluorescence.
The fluorescence was measured (Excitation peak wavelength: 490 nm; Emission peak
wavelength: 520 nm) using a Victor3 multilabel fluorescence microplate reader (Wallac)
every 5 min for 2.5h. The plate was incubated at 37°C with 5% CO2 between readings.

2.5 Assessment of PMVEC Barrier Integrity
Endothelial monolayer integrity was assessed in male murine WT PMVEC using
an in vitro model of PMVEC barrier function. WT PMVEC were seeded at a cell density
of 2.5x104 cells/insert on 1% gelatin-coated transwell cell-culture inserts (3.0 μM pore, #
CA62406-169, VWR Scientific Inc., Radnor, PA). PMVEC were grown to confluence in
supplemented DMEM growth medium (as described above) in 24-well cell-culture plates.
Baseline permeability of the PMVEC monolayer was assessed every second day using
transendothelial electrical resistance (TEER), which is the most sensitive measure of
paracellular permeability (e.g. to charged ions), to identify the time point at which a
stable monolayer formed.
Once a stable monolayer formed, baseline PMVEC barrier permeability was
comprehensively assessed using three complementary techniques: (i) TEER; (ii)
fluorescein isothiocyanate (FITC)-labelled dextran flux, which reflects small molecule
paracellular permeability; and (iii) EB-labelled albumin flux, which is a clinicially
relevant marker of both paracellular and transcellular permeability to large molecules. In
general, assessment of PMVEC permeability by all three complementary techniques was
conducted at five days after initial cell culture.
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2.5.1

Assessment of PMVEC Transendothelial Electrical
Resistance (TEER)
Intact endothelial barriers exhibit high levels of TEER, and decreased TEER is

indicative of physiological changes in PMVEC barrier function leading to increased
trans-PMVEC permeability. TEER was measured across PMVEC monolayers by placing
individual cell-culture inserts into the Endohm chamber (World Precision Instruments,
Sarasota, Florida) in order to measure the electrical resistance in Ohms (Ω) using the
EVOM2 Endothelial Voltohmmeter (World Precision Instruments, Sarasota, Florida).
TEER across empty individual inserts not containing cultured PMVEC was used as a
control to account for background resistance from the cell-culture inserts and this value
was subtracted from the TEER measurements obtained from cell-culture inserts
containing PMVEC.

2.5.2

Assessment of trans-PMVEC Macromolecular Flux
To further characterize PMVEC barrier function, movement of both small

(dextran; a small, 3 kDa sugar derivative) and large (albumin; a large, 67 kDa protein
found within blood) macromolecules from the upper chamber into the lower of the twochamber transwell system was assessed. Both FITC-labelled dextran and EB-labelled
albumin were added directly to the upper chamber of the transwell insert containing the
PMVEC monolayer, while the same concentration of unlabelled albumin was added to
the lower chamber to remove osmotic pressure. Following 1h, the transwell inserts were
removed, and the conditioned media of the lower chamber was collected. In order to
measure FITC-labelled dextran flux, the fluorescence of the conditioned medium was
measured (Excitation peak wavelength: 488 nm; Emission peak wavelength: 525 nm)
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using a Victor3 multilabel fluorescence microplate reader (Wallac). Background
fluorescence was measured in dextran-free DMEM. To measure EB-labelled albumin
flux, absorbance of the conditioned medium was measured (A620) by an iMark™
Microplate Reader (BioRad Laboratories Inc., Hercules, CA). Background absorbance
was measured in EB-albumin-free media.

2.6 Assessment of PMVEC Barrier Function following
PMVEC Stimulation
Previous work in my lab reported the effects of cytomix stimulation (30 ng/mL)
on TEER and trans-PMVEC macromolecular leak in PMVEC monolayers cultured on
transwell cell-culture inserts [83,112]. These studies demonstrated that maximal transPMVEC EB-labelled albumin leak occurred 4h following stimulation with cytomix [83].
To assess the effects of global metalloproteinase inhibitors on PMVEC barrier
dysfunction under septic conditions, male WT PMVEC were grown to confluence on
cell-culture inserts as described above and permeability assessed by all three
complementary techniques following a 4h stimulation with either PBS (vehicle control)
or cytomix (30 ng/mL) in the presence of vehicle control (dimethyl sulfoxide [DMSO] or
distilled water [dH2O]) or synthetic metalloproteinase inhibitor (GM6001 [10 – 100 μM,
#CC1010, EMD Millipore, St. Charles, MO], BB-94 [1 – 100 μM, #196440-5MG, EMD
Millipore], or TAPI-2 [10 – 100 μM, #579052-1MG, EMD Millipore]).

2.7 Assessment of PMVEC Cell Surface Adhesion
Molecules
Levels of PMVEC surface ICAM1, VCAM1 and E-selectin were examined in
WT and Timp3-/- PMVEC by flow cytometry using the Guava easyCyte HT Flow
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Cytometer (EMD Millipore). PMVEC were grown to confluence in 6-well cell culture
plates coated with 1% gelatin, and treated with PBS (vehicle control), cytomix (30
ng/mL), LPS (10 μg/mL) or a combination of both cytomix and LPS (30 ng/mL, 10
μg/mL, respectively) for 4h. Following stimulation, PMVEC were trypsinized with
0.05% Gibco trypsin-EDTA (1x) (Thermo Fisher Scientific), for 10 min, placed into
Falcon tubes and spun at 200 g x 5 min, washed with 0.02% BSA, and then resuspended
in 100 µL of 0.02% BSA. Fluorescently-labelled antibodies against ICAM1 (0.5 mg/mL;
#116111, BioLegend), VCAM1 (0.5 mg/mL; #105711, BioLegend), and E-selectin (0.2
mg/mL; #553751, BD Biosciences) were then added to each tube and the PMVEC placed
on a rotator for 40 min to ensure adequate staining. Unstained and stained PMVEC were
washed with PBS, resuspended in 250 µL of 0.02% BSA, transferred to a 96 well roundbottomed plate and assessed by flow cytometry.
The effect of metalloproteinase inhibition on cytomix-induced PMVEC surface
protein expression levels was also assessed. For these studies, PMVEC were treated with
GM6001, BB-94, or TAPI-2 (100 µM) as above, or appropriate vehicle control (DMSO
or dH2O) for 16 hours prior to cytomix stimulation.

2.8 Assessment of Polymorphonuclear Leukocyte (PMN)PMVEC Interaction
To examine PMN-PMVEC adhesion, WT and Timp3-/- PMVEC were grown to
confluence on 24-well cell culture plates coated with 1% gelatin and bone marrow PMN
were isolated from WT mice. Briefly, bone marrow was collected from the bones of WT
mice into eppendorf tubes and spun at 3000 x g for 1 min. PMN were then isolated by
density gradient centrifugation using 62% Percoll (#P4937, Sigma-Aldrich). Red blood
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cells (RBC) were subsequently lysed with RBC lysis buffer solution (#00-4333-57,
eBioscience), and the isolated PMN stained with calcein-AM (#17783, Sigma-Aldrich)
for 30 min at 37°C. PMVEC and PMN were then treated separately with either PBS
(vehicle control) or cytomix (10 ng/mL) for 4h. Following stimulation, PMN were added
to PMVEC at a ratio of 10:1. After 30 min, cells were washed 3x with PBS to remove
non-adherent PMN, and the adherent PMN and PMVEC monolayers lysed using 0.05%
trypsin-EDTA. Lysate was then transferred to a clear bottom 96-well black microplate
(#82050-754, VWR) and fluorescence measured using a Victor3 multilabel fluorescence
microplate reader (Excitation: 488 nm; Emission: 525 nm; Wallac). Percentage of total
neutrophil adhesion was determined by using a standard curve of labelled PMN.
Background fluorescence was determined using unlabeled PMVEC.

2.9 Statistical Analysis
Differences between groups were assessed by t-test or a One-Way ANOVA with
a Bonferroni post-hoc test for one independent variable, or by a Two-Way ANOVA with
a Bonferroni post-hoc test for two independent variables using GraphPad Prism 6.2.
Significance threshold was set at α = 0.05. Outliers were assessed using the Grubbs’ test.
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Chapter 3

3

Results

3.1 Timp and Metalloproteinase mRNA Expression in Wild
Type (WT) PMVEC
Previous studies demonstrated that septic PMVEC barrier dysfunction appeared to
peak after 4h cytomix-stimulation in vitro and in vivo [8,83,112]. Further, TIMP3
appeared to be required for normal PMVEC barrier function, as mice lacking TIMP3 had
increased basal PMVEC permeability [83]. Thus, PMVEC expression of all Timps and
key metalloproteinases was examined in PMVEC under basal conditions and 1, 2, and 4h
following in vitro and in vivo models of sepsis by qRT-PCR. Analysis of Timp1-4
expression found that Timp2 had the highest basal expression and Timp4 had the lowest
expression (Table 3-1; NOTE: Ct values of 35+ were considered as very low expression
and Ct values of 40+ were considered to be absent). Mmp2, Adam10 and Adam17
appeared to be expressed at high levels whereas basal expression of Mmp9 was fairly
low, and Mmp7 was not detected (Table 3-1). Basal expression levels of Timp1-4 and
metalloproteinases in PMVEC isolated from naïve WT mice ex vivo were similar to WT
PMVEC in vitro (Table 3-2).

3.1.1

Timp mRNA Expression is Altered in WT PMVEC under
Septic Conditions
Septic models had varying effects on Timp mRNA expression, with Timp4 mRNA

expression remaining undetectable under all septic conditions (Figure 3-1). PMVEC
stimulated with cytomix had significantly increased Timp1 mRNA expression by 4h poststimulation, but had no changes in Timp2 and -3 mRNA expression (Figure 3-1).
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Table 3-1: Average Basal (Threshold Cycle) Ct values for TIMP/metalloproteinase
messenger ribonucleic acid (mRNA) expression in isolated murine wild type (WT)
pulmonary MVEC (PMVEC) in vitro (n=22).
Timp1

Timp2

Timp3

Timp4

Hprt1

28.4

24.7

25.2

36.7

25.6

Mmp2

Mmp7

Mmp9

Adam10

Adam17

28.7

40+

36.1

25.6

27.1

Table 3-2: Average Basal Ct values for Timp/metalloproteinase mRNA expression in
isolated murine WT PMVEC isolated ex vivo (n=8).
Timp1

Timp2

Timp3

Timp4

Hprt1

38.2

31.7

29.7

38.2

31.4

Mmp2

Mmp7

Mmp9

Adam10

Adam17

34.3

40+

36.5

31.6

31.7
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Figure 3-1: Timp messenger ribonucleic acid (mRNA) expression is altered in wild
type (WT) PMVEC in vitro and ex vivo under septic conditions. Cytomix-stimulated
WT PMVEC had an increase in Timp1 expression over 4h vs. PBS control (data
expressed as relative quantitiy [RQ] of WT PBS). Lipopolysaccharide (LPS)-stimulated
WT PMVEC had an increase in Timp1 expression and a decrease in Timp3 expression
over 4h vs. PBS control (data expressed as RQ of WT PBS). Cytomix + LPS-stimulated
WT PMVEC had an increase in Timp1 and Timp3 expression over 4h vs. PBS control
(data expressed as RQ of WT PBS control). PMVEC from cecal ligation and perforation
(CLP)-septic WT mice had an increase in Timp1, Timp2, and Timp3 expression vs.
PMVEC from naïve WT mice (data expressed as RQ of WT naïve). Timp4 was not
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detected at sufficient levels in all conditions. * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and +
p<0.05 vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=5-8.
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LPS-stimulation of PMVEC significantly increased Timp1 mRNA expression by 4h poststimulation, had no effect on Timp2 mRNA expression, but significantly reduced Timp3
mRNA expression by 4h post-stimulation. The combination of cytomix and LPS resulted
in significant increases in Timp1 and -3 mRNA expression as early as 2h post-stimulation
and this increase continued at 4h; however, no effect was observed on Timp2 mRNA
expression (Figure 3-1).
PMVEC isolated from CLP-septic mice had significantly increased Timp1 and -3
mRNA expression as early as 2h post-CLP vs. PMVEC isolated from naïve mice, and
this increase remained significant at 4h post-CLP. Timp2 mRNA expression was
significantly increased by 1h post-CLP, but recovered to basal levels by 2h post-CLP
(Figure 3-1). Interestingly, in vitro the individual stimulations (i.e. cytomix or LPS
alone) caused significant changes to a single TIMP; however, the combined stimulation
of cytomix and LPS in vitro appeared to be more representative of what was observed in
vivo (Figure 3-1).

3.1.2

Metalloproteinase mRNA Expression is Altered in WT
PMVEC under Septic Conditions
Because Timp mRNA expression levels were significantly altered under septic

conditions, I next examined metalloproteinase mRNA expression. Cytomix stimulation of
PMVEC in vitro significantly increased Mmp9 and Adam17 mRNA expression by 4h
post-stimulation. Mmp2 and Adam10 mRNA expression did not change (Figure 3-2).
LPS-stimulated PMVEC had significantly increased Mmp9 and Adam17 mRNA
expression by 4h post-stimulation and no effect on Mmp2 and Adam10 mRNA expression
(Figure 3-2). The combination of cytomix and LPS significantly increased Mmp9 and
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Figure 3-2: Metalloproteinase mRNA expression is altered in WT PMVEC in vitro
and ex vivo under septic conditions. Cytomix-stimulated WT PMVEC had an increase
in Mmp9 and Adam17 expression over 4h vs. PBS control (data expressed as RQ of WT
PBS). LPS-stimulated WT PMVEC had an increase in Mmp9 and Adam17 expression
over 4h vs. PBS control (data expressed as RQ of WT PBS). Cytomix + LPS-stimulated
WT PMVEC had an increase in Mmp9 and Adam17 expression and a decrease in Adam10
over 4h vs. PBS control (data expressed as RQ of WT PBS). PMVEC from CLP-septic
WT mice displayed an increase in Mmp9 expression vs. PMVEC from naïve WT mice
(data expressed as RQ of WT naïve). * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05
vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=5-8.
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Adam17 mRNA expression by 4h post-stimulation, significantly decreased Adam10
mRNA expression by 4h post-stimulation, and had no effect on Mmp2 mRNA expression
(Figure 3-2).
PMVEC isolated from CLP-septic mice had significantly increased Mmp9 mRNA
expression by 2h post-CLP. Once again, Mmp2 and Adam10 mRNA expression did not
change; however, Adam17 mRNA expression had a trend towards increased expression.
Thus, while in vitro septic models led to significant changes in PMVEC-derived
metalloproteinase expression, only Mmp9 was significantly altered in the in vivo model
of sepsis (Figure 3-2).

3.2 Metalloproteinase Protein Activity in WT PMVEC under
Septic Conditions
My expression data suggests that the balance between PMVEC-derived TIMPs
and metalloproteinases is disrupted under septic conditions; however, these changes in
expression may not be indicative of overall changes in metalloproteinase activity, and
thus, altered degradation or cleavage of proteins critical to PMVEC barrier function and
PMN-PMVEC interaction. Either or both septic stimulations and expression
independently or collectively could affect metalloproteinase activity. To examine the
impact of septic stimulation and the resulting altered TIMP/metalloproteinase balance on
metalloproteinase activity, I assessed global metalloproteinase activity within PMVEC
lysates and in PMVEC-conditioned media, as well as the activity of a specific
metalloproteinase, ADAM17, within the cell lysate.
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3.2.1

Global Metalloproteinase Activity in the Conditioned Media is
not Altered under Septic Conditions
Multiple metalloproteinases expressed by PMVEC, including MMP2 and -9, are

considered soluble MMPs and as such, may be released from the cell into the surrounding
microenvironment. To examine the activity of these soluble metalloproteinases, I
assessed total metalloproteinase within the conditioned media from WT PMVEC under
basal conditions and after 4h of septic (cytomix, LPS, or a combination of both)
stimulation. Compared to PBS control, soluble metalloproteinase activity was not
significantly altered under septic conditions. However following stimulation with
cytomix or the combination of cytomix and LPS, there appeared to be a trend towards
decreased metalloproteinase activity (Cytomix: 7%; Cytomix + LPS: 10%; Figure 3-3).

3.2.2

Global Metalloproteinase Activity in PMVEC Lysate is not
Altered under Septic Conditions
While soluble metalloproteinases are detected in the conditioned media, many

metalloproteinases, including ADAMs, are found on the cell membrane. Further, soluble
metalloproteinases expressed by PMVEC but not yet secreted, or bound to the cell
surface through interaction with cell surface receptors such as integrins, are also
associated with the cellular compartment. Thus, I next investigated global
metalloproteinase activity within the PMVEC lysate. Surprisingly, compared to PBS
control, total metalloproteinase activity was not significantly altered under septic
conditions; however, there was a trend towards increased activity following cytomix
stimulation (9%; Figure 3-4).
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Figure 3-3: PMVEC-derived soluble metalloproteinase activity is not altered under
4h septic conditions. Left panel: Representative graph of metalloproteinase activity
(indicated by increase in relative fluorescence over time) in the conditioned media of WT
PMVEC under basal and septic conditions. Right panel: Area under the curve (AUC)
analysis revealed that compared to PBS control, PMVEC stimulated under septic
conditions for 4h had no significant change in soluble metalloproteinase activity.
However, PMVEC stimulated with cytomix and the combination of cytomix and LPS
appeared to have a trend towards decreased metalloproteinase activity (n=6).
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Figure 3-4: Total metalloproteinase activity in WT PMVEC lysate is not altered
under 4h septic conditions. Left panel: Representative graph of metalloproteinase
activity (indicated by increase in relative fluorescence over time) in the lysate of WT
PMVEC under basal and septic conditions. Right panel: AUC analysis revealed that
compared to PBS control, the lysate from PMVEC stimulated under septic conditions for
4 hours had no change in global metalloproteinase activity. However, PMVEC stimulated
with cytomix appeared to have a trend towards increased metalloproteinase activity
(n=4).
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3.2.3

ADAM17 Activity is Increased in WT PMVEC under Septic
Conditions
As showed in 3.1.2, PMVEC expression of Adam17, a metalloproteinase known

to be associated with the cell membrane, was significantly increased under septic
conditions, which suggests that the observed trend towards an increase in total
metalloproteinase activity in PMVEC lysate could be due to increased ADAM17 activity.
Analysis of PMVEC lysate ADAM17 activity revealed that ADAM17 activity was
significantly increased following the combined stimulation of cytomix and LPS
compared to PBS control (Figure 3-5). Further, there also appeared to be a trend towards
increased ADAM17 activity following both cytomix and LPS stimulation (Cytomix: 8%;
LPS: 6%; Figure 3-5).

3.3 Inhibition of Metalloproteinase Activity Reduces WT
PMVEC Barrier Dysfunction under Septic Conditions
Septic stimulation, including cytomix and LPS, is well known to promote
PMVEC barrier dysfunction [8,83,108,110,113,114]. Further, this PMVEC barrier
dysfunction appears to be associated with a shift in the expression of metalloproteinases
and TIMPs from the basal expression patters, and is also associated with increased
metalloproteinase activity, specifically, ADAM17. However, whether this increased
metalloproteinase activity is responsible for the septic PMVEC barrier dysfunction is
unknown. To address this, permeability across WT PMVEC was assessed in vitro under
septic conditions in the presence or absence of three global metalloproteinase inhibitors,
GM6001, BB-94 or TAPI-2. Specifically, WT PMVEC were stimulated with PBS
(vehicle control) or cytomix (30 ng/mL) for 4h in the presence of increasing
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Figure 3-5: A disintegrin and metalloproteinase (ADAM) 17 activity appears to be
increased in WT PMVEC lysate under 4h septic conditions. Left panel:
Representative graph of ADAM17 activity (indicated by increase in relative fluorescence
over time) in the lysate of WT PMVEC under basal and septic conditions. Right panel:
AUC analysis revealed that compared to PBS control, PMVEC stimulated with cytomix
and LPS together for 4h had significantly increased ADAM17 activity. PMVEC
stimulated with cytomix and LPS separately appeared to have a trend towards increased
ADAM17 activity. * p<0.05 vs. PBS, One-Way ANOVA followed by a Bonferroni posthoc test, n=4.
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concentrations of GM6001, BB-94 or TAPI-2 (1-100 uM) or their vehicle controls
(DMSO or dH2O) and TEER, as well as FITC-labelled dextran and EB-labelled albumin
flux across the PMVEC monolayers was measured. WT PMVEC stimulated with
cytomix for 4h was associated with a significant increase in PMVEC permeability as
measured by decreased TEER and increased dextran and albumin flux (Figure 3-6 and
3-7). Interestingly, compared to vehicle control, increasing concentrations of GM6001,
BB-94, and TAPI-2 had no effect on TEER (Figure 3-6). Further, compared to DMSO
control, increasing concentrations of GM6001 also had no effect on albumin and dextran
flux across WT PMVEC under septic conditions (Figure 3-7). However, BB-94
significantly reduced albumin flux vs. DMSO control at a concentration of 10 μM, and
this reduction persisted at higher concentrations (Figure 3-7). Further, treatment with
BB-94 also appeared to reduce dextran flux with a significant reduction observed at 25
µM (Figure 3-7). Compared to dH2O, increasing concentrations of TAPI-2 also led to
significantly reduced albumin and dextran flux at 25 μM (Figure 3-7).

3.4 Basal differences between WT vs. Timp3-/- PMVEC
Basal studies have demonstrated that basal Timp3-/- PMVEC permeability, as
measured by TEER and macromolecular flux, is significantly greater than WT PMVEC
[83]. Further, treatment of Timp3-/- PMVEC with a synthetic metalloproteinase inhibitor,
GM6001, partially restored this increased permeability suggesting that increase was at
least partly dependent on metalloproteinase activity [83]. Thus, I next began to further
characterize the impaired barrier function in Timp3-/- PMVEC assessing Timp and
metalloproteinase mRNA expression as well as metalloproteinase activity Timp3-/PMVEC vs. WT PMVEC under basal conditions. Analysis of Timp expression
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Figure 3-6: Transendothelial electrical resistance (TEER) is not altered following
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Figure 3-7: Septic macromolecular flux is reduced following treatment with specific
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found that Timp2 had the highest basal expression and Timp4 had the lowest expression
(Table 3-3). Mmp2, Adam10 and Adam17 appeared to be expressed at high levels
whereas basal expression of Mmp9 was fairly low, and Mmp7 was not detected (Table 33). Timp and metalloproteinase basal expression were similar in PMVEC isolated from
naïve Timp3-/- mice ex vivo (Table 3-4).

3.4.1

Metalloproteinase and Timp mRNA Expression in Timp3-/PMVEC is Similar to WT PMVEC under Basal Conditions
Analysis of metalloproteinase and Timp mRNA expression in WT and Timp3-/-

PMVEC in vitro under basal conditions revealed no significant differences between
genotypes, except for Timp3, which is not present in Timp3-/- PMVEC (Figure 3-8).
Similarly, in PMVEC isolated from naïve mice, compared to WT, Timp3-/- PMVEC had
no significance differences in Timp or metalloproteinase expression, except for Timp3
(Figure 3-9).

3.4.2

Metalloproteinase Activity Appears Decreased in Timp3-/- vs.
WT PMVEC under Basal Conditions
Analysis of global metalloproteinase activity in conditioned media from WT and

Timp3-/- PMVEC under basal conditions demonstrated significantly reduced
metalloproteinase activity in the conditioned media from Timp3-/- PMVEC compared to
WT PMVEC (15%; Figure 3-10A). Interestingly, no significant differences in global
metalloproteinase activity or in ADAM17 activity were noted between genotypes in the
cell lysate under basal conditions (Figure 3-10B and C).
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Table 3-3: Average Basal Ct values for Timp/metalloproteinase mRNA expression in
isolated murine Timp3-/- PMVEC in vitro (n=22).
Timp1

Timp2

Timp3

Timp4

Hprt1

28.4

25.0

-/-

36.4

25.5

Mmp2

Mmp7

Mmp9

Adam10

Adam17

28.5

40+

36.0

26.0

27.1

Table 3-4: Average Basal Ct values for Timp/metalloproteinase mRNA expression in
isolated murine Timp3-/- PMVEC ex vivo (n=5).
Timp1

Timp2

Timp3

Timp4

Hprt1

37.2

30.2

-/-

38.2

31.4

Mmp2

Mmp7

Mmp9

Adam10

Adam17

33.0

40+

35.4

30.0

30.5
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Figure 3-8: Timp and metalloproteinase mRNA expression is not altered in Timp3-/PMVEC vs. WT PMVEC at basal levels in vitro. No significant differences were
observed in Timp or metalloproteinase expression, except for Timp3, in Timp3-/- PMVEC
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vs. WT PMVEC. Data expressed as the RQ of WT control, * p<0.05 vs. WT, paired ttest, n=22.
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metalloproteinase expression, except Timp3, were found in Timp3-/- PMVEC vs. WT
PMVEC isolated from naïve mice. Data expressed as the RQ of WT control, * p<0.05 vs.
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Figure 3-10: Metalloproteinase activity appears reduced in Timp3-/- PMVEC vs. WT
PMVEC under basal conditions in vitro. Left panel: Representative graph of
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the
conditioned media (A) and lysate (B, C) of WT and Timp3-/- PMVEC under basal
conditions. Right panel: AUC analysis revealed that compared to WT, Timp3-/- PMVEC
had (A) significantly reduced soluble metalloproteinase activity, (B) no change in global
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metalloproteinase activity, (C) no change in ADAM17 activity. * p<0.05 vs. WT, paired
t-test, n=4-6.
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3.5 Timp and Metalloproteinase mRNA Expression in
Timp3-/- PMVEC
While no differences were observed in metalloproteinase and Timp expression
between WT and Timp3-/- PMVEC under basal conditions, TIMP3 has been previously
found to mediate pro-inflammatory signalling and as such, it is possible that the response
of Timp3-/- PMVEC to septic stimuli could be altered [49,98,100,101,115]. To assess this,
I next examined Timp and metalloproteinase expression data in Timp3-/- PMVEC under
septic conditions.

3.5.1

Timp mRNA Expression is Altered in Timp3-/- PMVEC under
Septic Conditions
PMVEC-derived expression of all Timps and key metalloproteinases was

examined in Timp3-/- PMVEC at 1, 2, and 4h following in vitro (cytomix, LPS, and both
cytomix and LPS) and in vivo (CLP) models of sepsis by qRT-PCR. Similar to WT
PMVEC, in Timp3-/- PMVEC, Timp1 mRNA expression was significantly increased at 4h
post-cytomix, as well as at 2 and 4h post-stimulation with both cytomix and LPS, while
Timp2 mRNA expression was not altered under septic conditions in vitro (Figure 3-11).
Further, Timp1 mRNA expression was significantly increased at 4h post-CLP in PMVEC
from Timp3-/- mice (Figure 3-11). Additionally, in PMVEC from Timp3-/- mice, Timp2
mRNA expression appeared to trend towards an increase at 1 and 2h post-CLP, but was
significantly reduced at 4h post-CLP (Figure 3-11).

3.5.2

Metalloproteinase mRNA Expression is Altered in Timp3-/PMVEC under Septic Conditions
I next examined metalloproteinase mRNA expression in Timp3-/- PMVEC under

septic conditions in vitro and in vivo. Cytomix stimulation of PMVEC significantly
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Figure 3-11: Timp mRNA expression is altered in Timp3-/- PMVEC in vitro and ex
vivo under septic conditions. Cytomix-stimulated Timp3-/- PMVEC had an increase in
Timp1 expression over 4h vs. PBS control (data expressed as RQ of PBS). LPSstimulated Timp3-/- PMVEC had no significant changes in Timp expression over 4h vs.
PBS control (data expressed as RQ of PBS). Cytomix + LPS-stimulated Timp3-/- PMVEC
had an increase in Timp1 expression over 4h vs. PBS control (data expressed as RQ of
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PBS). PMVEC isolated from CLP-septic Timp3-/- mice had an increase in Timp1
expression over 4h and significantly decreased Timp2 expression at 4h vs. PMVEC from
naïve Timp3-/- mice (data expressed as RQ of naïve). Timp3 and -4 were not detected at
sufficient levels under any condition. * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05
vs. 2 h, One-Way ANOVA followed by a Bonferroni post-hoc test, n=3-8.
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increased Mmp9 and Adam17 mRNA expression by 4h post-stimulation. Mmp2 and
Adam10 mRNA expression did not change (Figure 3-12). LPS-stimulated PMVEC had
significantly increased Mmp9 by 2h post-stimulation, and this increase remained
significant at 4h post-stimulation. Interestingly, Adam10 mRNA expression significantly
reduced by 1h post-stimulation, and this decrease remained significant at 2 and 4h poststimulation. Mmp2 and Adam17 mRNA expression did not change; however, Adam17
expression appeared to trend towards increased expression (Figure 3-12). Further, the
combination of cytomix and LPS significantly increased Mmp2, -9, and Adam17 mRNA
expression at 4h post-stimulation. Adam10 mRNA expression, however, remained
constant at all time points (Figure 3-12). Finally, PMVEC isolated from CLP-septic
Timp3-/- mice had significantly increased Mmp9 and Adam17 mRNA expression at 1 and
2h post-CLP; however, expression of both returned to basal levels at 4h post-CLP. No
significant differences in Mmp2 and Adam10 mRNA expression were observed in
PMVEC isolated from CLP-septic Timp3-/- mice (Figure 3-12).

3.6 Metalloproteinase Activity in Timp3-/- PMVEC under
Septic Conditions
Once again, my expression data suggests that the balance between PMVECderived TIMPs and metalloproteinases is disrupted under septic conditions; however,
these changes in expression may not be indicative of overall changes in metalloproteinase
activity. To examine the impact of the altered TIMP/metalloproteinase balance on
metalloproteinase activity, I assessed global metalloproteinase activity within the
conditioned media and within the cell lysate, as well as the activity of a specific
metalloproteinase, ADAM17, within the cell lysate under septic conditions.
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Figure 3-12: Metalloproteinase mRNA expression is altered in Timp3-/- PMVEC in
vitro and ex vivo under septic conditions. Cytomix-stimulated Timp3-/- PMVEC had an
increase in Mmp9 and Adam17 expression over 4h vs. PBS control (data expressed as RQ
of PBS). LPS-stimulated Timp3-/- PMVEC had an increase in Mmp9 expression and a
decrease in Adam10 expression over 4h vs. PBS control (data expressed as RQ of PBS).
Cytomix + LPS-stimulated Timp3-/- PMVEC had an increase in Mmp2, Mmp9 and
Adam17 expression over 4h vs. PBS control (data expressed as RQ of PBS). PMVEC
from CLP-septic Timp3-/- mice had an increase in Mmp9 and Adam17 expression over 4h
vs. PMVEC from naïve Timp3-/- mice (data expressed as RQ of naïve). * p<0.05 vs. PBS,
# p<0.05 vs. 1 h, and + p<0.05 vs. 2 h, One-Way ANOVA followed by a Bonferroni
post-hoc test, n=3-8.
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3.6.1

Global Metalloproteinase Activity in the Conditioned Media is
not Altered under Septic Conditions in Timp3-/- PMVEC
To examine the activity of soluble metalloproteinases, I assessed total

metalloproteinase within the conditioned media from Timp3-/- PMVEC under basal
conditions and after 4h of septic (cytomix, LPS, or a combination of both) stimulation.
Compared to PBS control, soluble metalloproteinase activity was not significantly altered
under septic conditions. However following stimulation, there appeared to be a trend
towards decreased metalloproteinase activity (Cytomix: 6%; LPS: 11%; Cytomix + LPS:
12%; Figure 3-13).

3.6.2

Global Metalloproteinase Activity in Timp3-/- PMVEC Lysate
is not Altered under Septic Conditions
I investigated global metalloproteinase activity within the cell lysate, which

contains many membrane bound metalloproteinases, as well as soluble
metalloproteinases, which have not been secreted, or bound to the cell surface through
interaction with cell surface receptors. Compared to PBS control, total metalloproteinase
activity was not significantly altered under septic conditions. However, following
cytomix stimulation and the combined stimulation of cytomix and LPS, there appeared to
be a trend towards decreased and increased metalloproteinase activity, respecitvely
(Cytomix: 10%; Cytomix + LPS: 23%; Figure 3-14).

3.6.3

ADAM17 Activity is not Altered in Timp3-/- PMVEC under
Septic Conditions
Expression of Adam17, a metalloproteinase known to be associated with the cell

membrane, was significantly increased under septic conditions, which suggests that the
observed trend towards an increase in total metalloproteinase activity in the cell lysate
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Figure 3-13: Timp3-/- PMVEC-derived soluble metalloproteinase activity is not
altered under 4h septic conditions. Left panel: Representative graph of
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the
conditioned media of Timp3-/- PMVEC under basal and septic conditions. Right panel:
AUC analysis revealed that compared to PBS control, PMVEC stimulated under septic
conditions for 4h had no significant change in soluble metalloproteinase activity.
However, PMVEC under septic conditions appeared to have a trend towards decreased
metalloproteinase activity (n=6).
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Figure 3-14: Total metalloproteinase activity in Timp3-/- PMVEC lysate is not
altered under 4h septic conditions. Left panel: Representative graph of
metalloproteinase activity (indicated by increase in relative fluorescence over time) in the
lysate of Timp3-/- PMVEC under basal and septic conditions. Right panel: AUC analysis
revealed that compared to PBS control, the lysate from PMVEC stimulated under septic
conditions for 4h had no change in global metalloproteinase activity. However, PMVEC
under cytomix and cytomix + LPS stimulation appeared to have a trend towards
decreased and increased metalloproteinase activity, respectively (n=4).
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could be due to increased ADAM17 activity. PMVEC stimulated under septic conditions
after 4h had no significant change in ADAM17 activity. However, PMVEC stimulated
with LPS and the combination of cytomix and LPS appeared to have a trend towards
increased activity (LPS: 23%; Cytomix + LPS: 52%; Figure 3-15).

3.7 Endothelial Barrier Dysfunction is Associated with
Increased Cell Surface Expression of PMVEC Cell
Adhesion Molecules
3.7.1

PMVEC Cell Adhesion Molecule mRNA Expression is
Increased in WT and Timp3-/- PMVEC under Septic
Conditions
Expression of Icam1, Vcam1, and Sele mRNA levels was examined in WT and

Timp3-/- PMVEC in vitro following stimulation with cytomix, LPS, or both for between
1-4h. Cytomix stimulation of WT and Timp3-/- PMVEC significantly increased Icam1,
Vcam1, and Sele (Figure 3-16). LPS stimulation of WT PMVEC significantly increased
Sele mRNA expression, as well as Icam1, Vcam1, and Sele mRNA expression in Timp3-/PMVEC (Figure 3-16). Icam1 and Vcam1 mRNA expression trended towards increased
expression in LPS-stimulated WT PMVEC (Figure 3-16). Under each septic condition,
Sele mRNA expression decreased at 2 and 4h in both WT and Timp3-/- PMVEC (Figure
3-16). Cytomix and LPS stimulation of WT PMVEC led to a significant increase vs. PBS
control in Icam1 and Vcam1 mRNA expression by 1h post-stimulation, which persisted at
2h and continued to increase at 4h post-stimulation. Sele mRNA expression significantly
increased by 1h post-stimulation, and remained significantly increased at 2 and 4h vs.
PBS control; however, Sele expression was decreased at 2 and 4h post-stimulation vs. 1h
post-stimulation (Figure 3-16). Timp3-/- PMVEC stimulated with both cytomix and LPS
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Figure 3-15: ADAM17 activity is not altered in Timp3-/- PMVEC lysate under 4h
septic conditions. Left panel: Representative graph of ADAM17 activity (indicated by
increase in relative fluorescence over time) in the lysate of Timp3-/- PMVEC under basal
and septic conditions. Right panel: AUC analysis revealed that compared to PBS control,
PMVEC stimulated under septic conditions for 4h had no significant change in ADAM17
activity. PMVEC stimulated with LPS and a combination of cytomix and LPS appeared
to have a trend towards increased ADAM17 activity (n=4).
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Figure 3-16: Septic models increase expression of PMVEC cell adhesion molecules
in vitro. Icam1, Vcam1, and Sele mRNA expression is significantly increased following
stimulation with cytomix, LPS, and cytomix + LPS over 4h time course in both WT and
Timp3-/- PMVEC. When focused on cytomix + LPS stimulated PMVEC, the increased
expression, however, appears to be of a greater magnitude in Timp3-/- PMVEC vs. WT
PMVEC. * p<0.05 vs. PBS, # p<0.05 vs. 1 h, and + p<0.05 vs. 2 h, One-Way ANOVA
followed by a Bonferroni post-hoc test, n=6-8.
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revealed similar trends in Icam1, Vcam1, and Sele mRNA expression over the entire time
course; however, compared to WT PMVEC, Timp3-/- PMVEC expression of cell
adhesion molecules appeared to be 1.5-4 fold increased under septic conditions (Figure
3-16).

3.7.2

Cell Surface Expression of PMVEC Cell Adhesion Molecules
is Increased in WT and Timp3-/- PMVEC under Septic
Conditions
Flow cytometry was used to examine the cell surface levels of ICAM1, VCAM1,

and E-selectin on WT and Timp3-/- PMVEC under basal and septic conditions. For these
studies, PMVEC were treated in vitro with PBS, cytomix, LPS, or a combination of both
cytomix and LPS for 4h. Compared to PBS control, ICAM1, VCAM1, and E-selectin
levels were increased under septic conditions in both WT and Timp3-/- PMVEC (Figure
3-17). Analysis of the geometric mean fluorescence intensity (MFI) demonstrated that, in
general, ICAM1, VCAM1, and E-selectin cell surface abundance increased significantly
under septic conditions in both WT and Timp3-/- PMVEC (Figure 3-18). Specifically,
ICAM1, VCAM1, and E-selectin MFI significantly increased in WT and Timp3-/PMVEC following stimulation with cytomix and the combination of cytomix and LPS.
ICAM1 and VCAM1 also significantly increased following LPS stimulation in WT
PMVEC with a trend towards increased expression in Timp3-/- PMVEC. Interestingly,
compared to WT PMVEC, ICAM1 cell surface levels were significantly reduced in
Timp3-/- PMVEC under basal as well as each septic condition – this decreased abundance
in the Timp3-/- vs. WT PMVEC was not seen for VCAM1 or E-selectin (Figure 3-18).
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Figure 3-17: Cell adhesion molecule abundance appears increased on the cell
surface of PMVEC under septic conditions in vitro. Representative flow cytometry
histograms from WT and Timp3-/- PMVEC demonstrated that PMVEC stimulated with
cytomix and LPS for 4h (dark grey histogram) had increased ICAM1, VCAM1 and Eselectin vs. PBS control (tan histogram). Further, under basal and under septic conditions,
ICAM appeared to be more abundant on WT vs. Timp3-/- PMVEC. Little background
fluorescence was observed in unstained cells (white histogram; n=4-5).
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Figure 3-18: Cell adhesion molecule abundance is significantly increased on the cell
surface of PMVEC under septic conditions in vitro. Analysis of the mean fluorescence
intensity (MFI) revealed that ICAM1, VCAM1 and E-selectin cell surface abundance is
significantly increased in WT and Timp3-/- PMVEC under septic conditions. Further,
under basal and septic conditions, ICAM cell surface abundance is significantly increased
in WT vs. Timp3-/- PMVEC. # p<0.05 vs. PBS, # p<0.05 vs. WT, Two-Way ANOVA
followed by a Bonferroni post-hoc test, n=4-5.
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3.8 Cell Surface Intercellular Adhesion Molecule (ICAM) 1
Deficiency in Timp3-/- PMVEC under Basal Conditions
Appears Metalloproteinase Independent
To begin to determine the mechanism through which TIMP3 regulates PMVEC
surface ICAM1 expression under basal conditions, WT and Timp3-/- PMVEC were
treated with global metalloproteinase inhibitors. Surprisingly, treatment with GM6001,
BB94 or TAPI-2 had no effect on ICAM1 cell surface abundance on either WT or Timp3/-

PMVEC compared to DMSO or dH2O control (Figure 3-19). Moreover, cell surface

ICAM1 remained significantly decreased on Timp3-/- vs. WT PMVEC in all treatment
groups (Figure 3-19 and 3-20). Additionally, no changes were observed in VCAM1 or Eselectin cell surface abundance in any of the treatment groups (Figure 3-20).

3.9 Timp-/- PMVEC have Decreased PMN Adhesion under
Basal and Septic Conditions
The decreased ICAM1 abundance on the surface of Timp3-/- PMVEC may
interfere with PMN adhesion as ICAM1 is a critical receptor for CD11b on the leukocyte
cell surface [116]. Thus, I next investigated the potential role of TIMP3 in regulating
PMN-PMVEC adhesion. For these studies, WT and Timp3-/- PMVEC as well as WT
PMN were stimulated separately with cytomix for 4h before being combined for 30 min
to measure static adhesion. Under basal conditions, PMN adhesion to WT PMVEC was
approximately 15% of PMN whereas adhesion to Timp3-/- PMVEC was approximately
10% (Figure 3-21). Cytomix stimulation significantly increased PMN adhesion to both
WT and Timp3-/- PMVEC (31% and 24%, respectively (Figure 3-21). However, under
both basal and septic conditions, significantly fewer PMN adhered to Timp3-/- vs. WT
PMVEC (Figure 3-21).
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Figure 3-19: Global metalloproteinase inhibitors have no effect on PMVEC
intercellular adhesion molecule (ICAM) 1 cell surface abundance in vitro.
Representative flow cytometry histograms from WT and Timp3-/- PMVEC demonstrated
that compared to vehicle control (DMSO and dH2O; tan histogram), treatment with
GM6001, BB-94, and TAPI-2 (black histogram) had no effect on ICAM1 cell surface
abundance on WT and Timp3-/- PMVEC under basal conditions (n=3).
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Figure 3-20: Global metalloproteinase inhibitors have no effect on the cell surface
abundance of cell adhesion molecules on PMVEC in vitro. Analysis of MFI revealed
that compared to vehicle control (DMSO and dH2O), GM6001, BB-94, and TAPI-2 had
no effect on ICAM1, VCAM1, or E-selectin cell surface abundance on WT and Timp3-/PMVEC under basal conditions. Further, Timp3-/- PMVEC had significantly decreased
cell surface ICAM1 abundance vs. WT PMVEC under all conditions. * p<0.05 vs. WT,
Two-Way ANOVA followed by a Bonferroni post-hoc test, n=3.
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Figure 3-21: Timp3-/- PMVEC have reduced polymorphonuclear leukocyte (PMN)
adhesion. Compared to PBS, WT and Timp3-/- PMVEC have significantly increased
PMN adhesion; however, Timp3-/- PMVEC have significantly reduced PMN adhesion
under both basal and under septic (cytomix, 30 ng/mL) conditions compared to WT
PMVEC. * p<0.05 vs. PBS and # p<0.05 vs. WT, Two-Way ANOVA followed by a
Bonferroni post-hoc test, n=7.
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Chapter 4

4

Discussion

4.1 Summary of Findings
Sepsis is a common and serious condition characterized by life-threatening organ
dysfunction caused by a dysregulated host response to infection [1]. Excessive
inflammation causes pathophysiological changes, including increased microvascular
permeability, leading to organ damage and dysfunction distant to the site of infection. In
particular, the accumulation of alveolar protein-rich edema observed in sepsis-induced
ARDS is thought to be caused by injury and dysfunction of PMVEC and the alveolar
epithelium due to excessive inflammation, characterized by a loss of structural integrity
and resulting barrier dysfunction [11,12]. PMVEC are critical in maintaining homeostatic
microvascular function by monitoring vascular tone, and controlling both the migration
of circulating cells and the movement of macromolecules across the intact microvascular
barrier into the lung [14,20–23]. Many mechanisms of septic PMVEC injury and
dysfunction have been described. The endogenous mechanisms protecting against sepsisinduced PMVEC dysfunction, however, are not well defined.
Thus, I sought to investigate the metalloproteinase-dependent role of PMVECderived TIMPs in the regulation of normal and septic murine microvascular barrier
function. My data suggest that the balance between TIMPs and metalloproteinases is
disrupted under septic conditions, leading to increased metalloproteinase activity and
PMVEC barrier dysfunction. Furthermore, disruption of this balance (loss of TIMP3) is
associated with impaired PMN recruitment. Therefore, this study demonstrates that
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TIMPs may mediate a novel, endogenous mechanism that promotes PMVEC barrier
function under healthy conditions, and that this homeostatic mechanism may be disrupted
under septic conditions.

4.2 Contributions of Research to Current State of
Knowledge
4.2.1

TIMP/Metalloproteinase Levels in Septic PMVEC
Previous studies have demonstrated that stimulation of murine WT PMVEC

monolayers in vitro with cytomix at a concentration of 30 ng/mL led to significant barrier
dysfunction, as measured by decreased TEER and enhanced trans-PMVEC EB-labelled
albumin and FITC-labelled dextran flux, by 4h post-stimulation [83]. Thus, Timp and
metalloproteinase mRNA expression levels were examined in WT and Timp3-/- PMVEC,
over the same timeline in order to assess the role of TIMPs in sepsis-induced PMVEC
dysfunction. The assessment of Timp mRNA expression following cytomix, LPS (10
μg/mL), or a combination of both revealed septic WT PMVEC express significantly
higher Timp1 mRNA levels than PBS-treated WT PMVEC. Significant alterations in
Timp3 mRNA expression levels, which depended on the septic stimuli, were also
observed compared to PBS-treated WT PMVEC. Further, Timp2 mRNA expression did
not change under various septic conditions, and Timp4 mRNA expression was not
detected in WT PMVEC.
Overall, my data demonstrates the importance of TIMPs in pulmonary
microvasculature, with TIMP1, -2, and -3 all being expressed under basal conditions.
TIMP expression varies in the different vascular beds throughout the body, including
both micro- and macrovascular beds; however, all TIMP family members are expressed
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within at least one vascular bed supporting the broad importance of TIMPs in EC
function. For example, TIMP1, -3, and -4 are expressed by murine brain MVEC, and
TIMP1, -2, and -3 are expressed by human EC isolated from the aorta, iliac artery, and
coronary artery [80–82]. Additionally, TIMP3 is expressed by murine PMVEC; however,
TIMP2 and -4 do not appear to be expressed by human PMVEC [83,84]. Interestingly,
while my data supports the observed lack of TIMP4 expression by PMVEC, it clearly
demonstrates constitutive Timp2 mRNA expression by murine PMVEC. One potential
reason for these disparate findings may be due to species differences as well as
differences in mRNA vs. protein expression as Shen and colleagues examined TIMP2
protein expression in human PMVEC [84].
TIMP expression appears to be differentially regulated under conditions of
infection and organ injury [53,67,80,81,83,88,90,103]. My observed increase in Timp1
mRNA expression in septic WT PMVEC is consistent with previous studies in other
vascular beds. Specifically, treatment of murine brain MVEC with IL1β and TNFα, or
with homocysteine, have been found to increase Timp1 mRNA expression [80,81].
Moreover, TIMP1 levels in serum have been found to be increased in severe sepsis in
humans [92,93]. Thus, these previous studies combined with the strong increase in Timp1
expression seen in my dual stimulation in vitro, as well as CLP-sepsis in vivo, strongly
suggest a potential role for PMVEC-derived TIMP1 in tissue injury and sepsis.
The decrease in Timp3 mRNA expression in LPS-stimulated WT PMVEC is
consistent with previous studies, in which TIMP3 expression (mRNA and protein) was
significantly decreased in murine brain MVEC and PMVEC following treatment with
IFNγ, IL1β, and TNFα [80,83]. Conversely, my finding that Timp3 mRNA expression
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increased in PMVEC stimulated with both cytomix and LPS, similar to the observed
increase in expression in CLP-septic PMVEC, suggests that more intense septic
stimulation is required to induce Timp3 expression. IL1β and TNFα act synergistically,
and the combination of both have led to significantly greater inflammation in human
gingival fibroblasts compared to LPS stimulation or either cytokine alone [117]. In
human sepsis, as well as murine CLP-sepsis in vivo, both cytokines and LPS are present,
collectively contributing to excessive inflammation and tissue/organ injury [118,119].
Therefore, an in vitro model using both cytokines and LPS may be more reflective of the
in vivo conditions during sepsis.
The combination of LPS and IFNγ, IL1β, and TNFα was also found previously to
maximally upregulate nitric oxide (NO) synthase (NOS) expression in hepatocytes [120].
In addition, the combination of LPS and cytokines (TNFα, IL1β and IL6) incubated
together induced a greater decrease in sarcomere shortening in isolated cardiomyocytes
compared to stimulation with LPS or individual cytokines alone demonstrating a
compounding effect [121]. Collectively, my data shows a greater increase in Timp1
mRNA expression in PMVEC stimulated with a combination of cytokines and LPS than
PMVEC stimulated with either individually. Timp3 mRNA expression is also induced at
higher levels in PMVEC stimulated with both cytomix and LPS, which is additionally
seen in CLP-sepsis in vivo. Overall, combined septic stimulation in vitro more closely
reflected Timp1 and -3 mRNA expression in PMVEC from in vivo CLP-septic mice,
suggesting a more effective model than cytomix or LPS individually.
My examination of metalloproteinase mRNA expression in each septic model
revealed septic WT PMVEC express significantly greater Mmp9 and Adam17 mRNA
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levels, whereas Mmp2 and Adam10 mRNA expression levels remain stable. Generally,
my data are supported by previous studies. For example, stimulation of brain EC with
TNFα and IL1β selectively upregulates MMP9 production, but does not alter MMP2
expression [54]. Further, MMP9 expression is also increased in HUVEC following
bacterial infection and in brain MVEC following viral infection, as well as in patients
with septic shock [43,57,58]. Additionally, ADAM17 expression has been found to be
upregulated in murine brain EC following stimulation with multiple pro-inflammatory
cytokines (i.e. TNFα, IL1β, IFNγ), and in human PMVEC following stimulation with
LPS [55,56]. Thus, MMP9 and ADAM17 expression by PMVEC appears to be highly
responsive to inflammatory stimuli suggesting a critical role for these metalloproteinases
in septic PMVEC dysfunction.

4.2.2

Metalloproteinase-Dependent Loss of Endothelial Barrier
Function
My lab has previously reported that PMVEC barrier function is impaired both in

vitro and in vivo under septic conditions [8,108,110,114,122,123]. PMVEC activation by
inflammatory cytokines leads to increased paracellular permeability, predominantly
through the disruption of inter-PMVEC junctions and actin cytoskeleton-driven PMVEC
retraction [14,16,20,21,23,31,104,124–127]. There are many mechanisms involved in
PMVEC barrier dysfunction following sepsis, including VE-cadherin internalization and
cleavage, as well as actin cytoskeleton polymerization and reorganization
[14,20,21,23,38,104,128–131]; however, endogenous mechanisms protecting against
sepsis-induced PMVEC barrier dysfunction are not well understood.
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Metalloproteinases, which have the ability to cleave multiple extracellular
proteins associated with inflammation, as well as proteins involved in cell-cell and cellECM interactions, have been found to be expressed by EC and this expression is altered
under the setting of infection and inflammation, which is supported by my data.
However, metalloproteinases are regulated at multiple levels, including secretion as
zymogens and subsequent extracellular activation following secretion [44,47,95]. Thus,
changes in expression may not be consistently reflected in changes in metalloproteinase
activity. Mmp9, a soluble metalloproteinase, was consistently upregulated with regards to
mRNA expression in every septic model, yet total soluble metalloproteinase activity in
the PMVEC-conditioned media was not altered under septic conditions in vitro. In
addition, the PMVEC lysate, which includes both membrane bound and intracellular
soluble metalloproteinases, did not exhibit enhanced metalloproteinase activity under
septic conditions, even though Mmp9 and Adam17 mRNA expression were both
upregulated. This disconnect between metalloproteinase expression and activity has been
recognized, and suggests metalloproteinase activity may be significantly regulated posttranslationally as metalloproteinases are predominantly secreted as inactive zymogens
[47].
My examination of metalloproteinase activity under septic conditions found that
while global metalloproteinase activity associated with the conditioned media or with the
cell lysate remained unchanged, combined stimulation of WT PMVEC led to
significantly increased ADAM17 activity. Importantly, this data demonstrates that the
observed changes on ADAM17 mRNA expression are reflective of functional changes in
ADAM17 levels (i.e. increased activity). It is interesting, however, that despite increased
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ADAM17 activity the total metalloproteinase activity was not significantly increased,
suggesting that the activity of other specific metalloproteinases may be decreased under
septic conditions. Further, because the cell lysate was used, it is important to note that
ADAM17 activity included both the membrane bound protein as well as intracellular
fraction, although it is unclear which was more active. Biologically, ADAM17 shedding
events can increase in occurrence without increasing the quantity of membrane bound
protein via an increase in cellular ADAM17 activity [132].
Although it is unclear why total metalloproteinase activity does not change under
septic conditions, my studies clearly demonstrate that inhibition of metalloproteinases
with synthetic metalloproteinase inhibitors in WT PMVEC under septic conditions
attenuates septic microvascular barrier dysfunction. BB-94, a potent broad-spectrum
inhibitor for MMP1, -2, -3, -7, -9, -14 and ADAM17, reduced albumin and dextran flux
by 50% in cytomix-stimulated WT PMVEC [133]. This is consistent with the literature as
previous studies found that BB-94 significantly reduced alveolar-capillary leakage in rats
in pancreatitis-associated lung injury, as well as BBB leakage in rats following either
acute pancreatitis or methamphetamine treatment [134–136]. My finding that TAPI-2, a
potent hydroxamate-based inhibitor of MMPs and ADAM17, reduces albumin and
dextran flux by 40% in cytomix-stimulated WT PMVEC is also supported by previous
studies [137]. Administration of TAPI-2 was found to significantly attenuate
bronchoalveolar fluid protein and TNFα levels in mice following hypercapnia acidosis
[138,139].
Interestingly, I also found that GM6001, another broad-spectrum
metalloproteinase inhibitor, had no effect on microvascular leak in cytomix-stimulated
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WT PMVEC. This is in contrast to previous studies, which have demonstrated the ability
of GM6001 to inhibit vascular permeability. Specifically, treatment of HUVEC with
GM6001 following recombinant TNFα-induced upregulation of metalloproteinase
activity rescued the increase in permeability as measured by macromolecular flux
[41,42]. Similarly, treatment of murine cerebrovascular EC with GM6001 following both
homocysteine injection in vitro and acute liver failure with azoxymethane in vivo resulted
in decreased microvascular leak due to the reversal of degradation of tight junction
adhesive protein and F-actin formation through the inhibition of MMP9 [73,74]. Finally,
previous work from my lab demonstrated that the enhanced basal leak across Timp3-/PMVEC was attenuated by treatment with GM6001. The reason for the apparent
difference between my current study and previous work on the effects of GM6001 on EC
barrier dysfunction is unclear. However, one potential mechanism could be due to the
metalloproteinases expressed and active in the different vascular beds or in different
models of injury/inflammation. EC from the micro- and macrovasculature have different
biological properties. For example, EB-albumin leak was significantly higher across
HUVEC than human PMVEC under basal and septic (LPS or cytomix) conditions [108].
HUVEC treated with GM6001 had reduced dextran permeability compared to untreated
HUVEC [42]. It is unclear which metalloproteinases are responsible for this permeability;
however, my data suggests they are not inhibited well by GM6001. This current data
suggest that ADAM17 may be a critical mediator of barrier dysfunction in the lung
microvasculature during sepsis. This supports a previous study, which demonstrated that
ADAM17 is involved in the regulation of vascular permeability during LPS-induced
acute lung injury in murine MVEC in vivo, and its inhibition with GW280264X, an
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ADAM17-specific metalloproteinase inhibitor, or its absence in Adam17-/- mice, resulted
in significantly reduced edema formation and vascular permeability [56].
One mechanism through which metalloproteinases can mediate loss of PMVEC
barrier function is through cleaving proteins associated with endothelial adherens and
tight junctions, such as VE-cadherin, occludin, ZO1, and JAMs as well as other crucial
adhesive junctional proteins [41,42,56,61–64]. MMP7, ADAM10, and -12 actively
cleave VE-cadherin [42,62], while MMP2 and -9 are capable of cleaving occludin and
ZO1 resulting in microvascular dysfunction via increased paracellular permeability
[61,63]. MMPs also target the components of the surrounding ECM, including
fibronectin, laminin, and type IV and V collagens, leading to disrupted endothelial–ECM
interactions and increased vascular permeability [65–70]. Thus, these studies suggest
increased metalloproteinase activity drives MVEC dysfunction through the proteolytic
processing of integral MVEC structural determinants (i.e. the ECM), resulting in MVEC
barrier dysfunction and enhanced microvascular leak.
In addition to changes in metalloproteinase expression, metalloproteinase activity
is also regulated by TIMPs. Surprisingly, my data demonstrated that while the overall
expression of Timps was increased in PMVEC under septic conditions, sepsis was also
associated with an increase in specific metalloproteinase activity. The four TIMPs have
overlapping abilities to inhibit metalloproteinases, but also exhibit varying degrees of
specificity. TIMP1 is secreted as a soluble inhibitor, and predominantly targets MMPs,
which are mostly soluble [50,95]. My data showed that metalloproteinase activity in the
conditioned media may be decreasing, which could be indicative of TIMP1 expression as
TIMP1 is generally found in body fluids (i.e. serum), especially under septic conditions
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[93,140,141]. Further, TIMP3 is known to inhibit ADAM17, which actively processes
and cleaves membrane bound pro-TNFα to yield the soluble inflammatory cytokine
TNFα [142,143]. While the increased ADAM17 activity in the presence of increased
Timp3 expression is surprising, it is possible that TIMP3 upregulation in septic PMVEC
in vitro and in vivo is a compensatory mechanism to limit or restrict ADAM17 activity
and thereby promote maintenance of stable PMVEC barrier function.
In addition, the observed differences in Timp3 mRNA expression may reflect
different functions for TIMP3 within the septic microenvironment and during the time
course of sepsis. For example, under basal conditions, TIMP3 appears to have a critical
role in promoting PMVEC barrier function, at least in part through regulation of VEcadherin localization [83]. TIMP3, however, may also have a role in mediating the initial
inflammatory response to an infection. Specifically, TIMP3 has been found to inhibit
shedding of VCAM1 from the surface of aortic EC following treatment with IL1β, TNFα,
or the phorbol ester PMA [106]. Aortic EC from Timp3-/- mice had increased VCAM1
shedding compared to aortic EC from WT mice, and this inhibition of VCAM1 shedding
by TIMP3 was likely through inhibition of ADAM17, as the TIMP3 dependent effect was
lost under conditions of ADAM17 knockdown [106]. Thus, TIMP3 appears to be a
critical regulator of MVEC dysfunction following tissue injury/infection, including
protection against loss of MVEC barrier function and regulation of PMN-PMVEC
interactions.

4.2.3

TIMP3 Regulation of PMN-PMVEC Interaction
My studies demonstrate that endothelial cell adhesion molecules, such as ICAM1,

VCAM1 and E-selectin, are significantly upregulated in septic WT and Timp3-/- PMVEC.
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This supports previous studies that found that both ICAM1 and VCAM1 expression on
the endothelial cell surface was induced by the release of pro-inflammatory cytokines
from macrophages at the site of infection, including TNFα and IL1β [144–147].
Additionally, LPS was found to stimulate translocation of the transcription factor nuclear
factor κB (NFκB) to the nucleus to initiate transcription of pro-inflammatory cytokines
and increase endothelial expression of ICAM1, both of which are associated with
increased endothelial permeability [13,16].
Interestingly, my data shows that Timp3-/- PMVEC express significantly less
ICAM1 on their cell surface under both basal and septic conditions compared to WT
PMVEC, and this was associated with significantly weaker adhesion to PMN, again,
under both basal and septic conditions. Previously, ICAM1 deficient mice were found to
exhibit impaired peritoneal neutrophil migration in response to chemical peritonitis [148].
Additionally, mice with a deficiency in both ICAM1 and P-selectin showed a significant
reduction in neutrophil migration in response to myocardial ischemia and reperfusion
[149]. Other studies, however, suggest that ICAM1 is not necessary for PMN adhesion to
EC and extravasation into tissues following infection. Specifically, neutrophil migration
into the alveolar spaces during acute Streptococcus pneumoniae-induced pneumonia was
not significantly altered in P-selectin/ICAM1 double deficient mice vs. WT mice [150].
Further, lung ICAM1 was required for spontaneous intravascular effector lymphocyte
entrapment, but not for neutrophil entrapment or emigration following instillation of
endotoxin [151]. Collectively, my data complements these previous studies and provides
further evidence to support a role for ICAM1 in regulation of PMN-PMVEC interaction.
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My studies also provide insight into a potential mechanism regulating PMVEC
surface ICAM1 expression as the amount of ICAM was significantly less on Timp3-/PMVEC compared to septic WT PMVEC. ICAM1 is constitutively expressed on the cell
surface of many cell types, including EC, and it is upregulated primarily through
increased transcription [152]. A number of inflammatory mediators including
proinflammatory cytokines (IFNγ, IL1β, and TNFα), retinoic acid, ROS and virus
infection activate ICAM1 transcription under inflammatory and injurious conditions
[152]. My data demonstrated significant PMVEC upregulation of ICAM1 mRNA and
protein under septic conditions in vitro, which supports these previous studies. However,
this data also suggests that Icam1 mRNA expression may not always correlate with cell
surface ICAM1 levels. Specifically, Timp3-/- PMVEC stimulated with cytomix had 1.4fold more expression than WT PMVEC; LPS had 1.3-fold less expression than WT
PMVEC; cytomix and LPS had 4-fold more expression than WT PMVEC. However, cell
surface ICAM1 levels were similar in PMVEC under each condition, with a significant
decrease observed in Timp3-/- vs. WT PMVEC. In addition, Icam1 mRNA expression was
upregulated the most in PMVEC stimulated with both cytomix and LPS, and the least in
PMVEC stimulated with LPS. However, cell surface quantity of ICAM1 was upregulated
approximately the same under each septic condition.
One mechanism regulating cell surface ICAM1 may be proteolytic cleavage
[153,154]. For example, MMPs have previously been found to shed ICAM1 from the cell
surface under inflammatory conditions [153]. Additionally, human leukocyte elastase,
which has been found to cause tissue destruction in a number of inflammatory diseases,
also sheds ICAM1 from the cell surface [154]. However, treatment with the broad-

89

spectrum metalloproteinase inhibitors GM6001, BB-94, and TAPI-2 had no effect on
Timp3-/- cell surface ICAM1, which suggests that the decreased ICAM1 on Timp3-/PMVEC was not due to increased metalloproteinase activity. TIMPs have also been
found to have metalloproteinase-independent functions. For example, TIMP3 inhibits cell
proliferation, binding directly to VEGFR2 on EC and blocking VEGF-VEGFR2
interaction, thereby inhibiting phosphorylation of VEGFR2 and downstream signalling
leading to decreased EC proliferation [95]. Further, VEGFR2 activation in response to
VEGF was also reduced by overexpression of a mutant TIMP3 that lacked the ability to
inhibit MMPs suggesting that TIMP3 inhibition of VEGF signaling is a
metalloproteinase-independent function [95]. Similarly, TIMP3 also binds the ANG II
type 2 receptor, and the presence of both inhibits HUVEC proliferation and angiogenesis
through inhibition of PKC and endothelial NOS (eNOS) [155].
Although there are no known mechanisms to explain the reduced ICAM1 on the
cell surface of Timp3-/- PMVEC, one proposed mechanism could involve ADAM17.
Previous studies have targeted ADAM17 to shed VCAM1 and ICAM1 from the cell
surface of EC. PMA stimulation of heart and aortic EC induced VCAM1 shedding via
ADAM17 [78]. Further investigation determined that PMA stimulated aortic EC from
Timp3-/- mice had increased VCAM1 shedding compared to stimulated WT mice,
suggesting TIMP3-dependent inhibition of ADAM17 [106]. However, my data does not
support this due to the lack of observed differences in ADAM17 activity between WT
and Timp3-/- PMVEC lysate, as well as the lack of observed differences in cell surface
ICAM1 on Timp3-/- PMVEC treated with GM6001, BB-94, or TAPI-2, suggesting a
metalloproteinase-independent mechanism.
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4.2.4

Role of TIMP3 in TIMP/Metalloproteinase Balance
In general, the primary function of TIMPs is thought to be inhibition of

metalloproteinase activity [47,95,96]. Further, shifting the balance between TIMPs and
metalloproteinases in favour of TIMPs is thought to regulate and reduce inflammation
and injury, while a shift in favour of metalloproteinases is thought to cause organ damage
and dysfunction [46,90,93,98,100,101]. For example, Timp3-/- mice have been found to
have decreased bronchiole branching and enhanced activity of MMPs throughout lung
development, leading to erratic focal ECM proteolysis [100,101]. In addition, lung
inflammation from bleomycin-induced injury persisted nearly four-times as long in
Timp3-/- mice, and was associated with upregulated MMP activity and greater neutrophil
chemotactic activity compared to WT mice [98]. In contrast, mice with a specific MMP
deficiency tend to have reduced morbidity and mortality in models of infection and
injury. Mmp9-/- mice were resistant to endotoxin-induced shock following endotoxemia
[156]. Bacterial endotoxin-induced systemic inflammation was considerably repressed in
mice lacking MMP3 [157]. MMP8 and -13 deficient mice were highly resistant to lethal
effect of LPS and CLP, with the latter being associated to reduced TNF release [43].
Interestingly, metalloproteinase activity data in Timp3-/- PMVEC in the current
report shows a shift in favour of TIMPs. Soluble metalloproteinase activity decreases in
Timp3-/- PMVEC basally, suggesting that TIMP1, a strong inhibitor of soluble MMPs, is
basally expressed at a sufficient quantity to inhibit these MMPs. However, I only
assessed the expression of a handful of metalloproteinases, and it is possible that there
could be differences in expression of other metalloproteinases (i.e. decreased expression),
which would account for the observed decrease in activity under basal conditions. Total
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metalloproteinase activity in Timp3-/- PMVEC lysate did not differ vs. WT lysate, and
one possibility is that other TIMPs may compensate for the lack of metalloproteinase
inhibition by TIMP3 in the Timp3-/- PMVEC. My studies, however, found no evidence of
compensation in Timp1 and -2 mRNA expression in Timp3-/- PMVEC basally, which
suggests that compensation is not involved.
Further, there is the potential for redundancy in the inhibition profiles between
TIMPs. However, while in vitro studies have demonstrated overlapping
metalloproteinase inhibition profiles (i.e. both TIMP1 and TIMP3 have been implicated
in the regulation of MMP7 activity and thus, in the absence of TIMP3, TIMP1 may be
able to inhibit MMP7 activity even without evidence of increased expression), there are
differences that exist between TIMPs in their ability to inhibit specific
metalloproteinases, especially ADAMs [79,95,97]. For example, TIMP1 does not appear
to be an effective inhibitor of the membrane type MMPs (MT-MMPs; MMP14, -15, -16,
-17, -24, and -26) [50]. Additionally, TIMP3 is unique from other TIMPs as it is a very
strong inhibitor of ADAMs and, currently, is the only known inhibitor of ADAMTSs
[50]. As such, it is surprising that ADAM17 activity was not significantly increased in
Timp3-/- PMVEC basally. Further, this lack of change in ADAM17 activity in Timp3-/PMVEC makes it unclear whether ADAM17 is responsible for the previously reported
increase in basal microvascular albumin flux in Timp3-/- PMVEC as a decrease in
ADAM17, as well as ADAM10, have been previously demonstrated to reduce vascular
permeability [42,56,83]. However, one caveat is that my analysis of ADAM17 expression
was in total cell lysate and not solely cell membrane associated. As such, it is unclear if
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ADAM17 activity was seen intracellularly in WT PMVEC from ADAM17 being
processed or transported to the cell membrane.

4.3 Limitations and Future Directions
4.3.1

Study Limitations
Many of my experiments were done entirely in vitro, and thus, under static

conditions. However, in an in vivo setting, several external forces, such as hemodynamic
stimuli including shear stress and changes in vessel size can affect PMVEC physiology
and responses to inflammatory stimuli (i.e. sepsis). Modulation of blood flow is achieved
by the release of vasoconstrictors (i.e. angiotensin-converting enzyme, endothelin) and
vasodilators (i.e. NO, prostacyclin) in order to regulate vascular resistance and systemic
blood pressure [15,17]. Adhesive junctional proteins, such as VE-cadherin, may also act
as flow sensors and transmit intracellular cues that signal the cell to react to changing
conditions [21]. Due to technological limitations, I was not able to replicate a flow model
that PMVEC would encounter in their native conditions. However, my use of multiple in
vitro models of septic stimulation created various environments for the endothelium to
respond to, one of which appears to be a strong representation of a septic environment in
vivo based on my ex vivo expression analysis. Overall, I believe that the use of multiple
models strengthened my in vitro analysis, and was also supported by direct ex vivo study
of PMVEC isolated from septic mice.
Although TNFα, IL1β, and IFNγ are seen in human sepsis, they are considered to
be pro-inflammatory cytokines, and not sepsis-specific. Previous studies have identified
significant increases in several other cytokines, including monocyte chemotactic protein
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1, IL6 and -8, granulocyte colony-stimulating factor, hepatocyte growth factor, and
macrophage inflammatory protein 1β, in plasma from patients with severe sepsis [158].
Using a mixture of these sepsis-specific cytokines, in conjunction with the current
cytomix, may create a more accurate model of sepsis in vitro.
Additionally, PMVEC were cultured on 1% gelatin coated transwell inserts and
wells in order to mimic an extracellular matrix for the cells to adhere to. The ECM,
however, is a complex network, composed of many different components in vivo
including collagens, gelatin, fibronectin, laminin, and elastin. These many components
mediate PMVEC-ECM interaction and downstream signalling through integrins,
releasing cryptic ECM fragments, which activate cell signalling and releasing sequestered
growth factors [49,101]. In order to mimic physiological conditions present in vivo, a
variety of ECM components, including collagens, elastin, proteoglycans, and fibronectin,
can be used in cell culture. Furthermore, the glycocalyx is known to be an important
regulator of endothelial function, forming a significantly thicker pulmonary endothelial
surface layer compared to other regions in the systemic circulation [25]. This endothelial
surface layer is critical to inflammation, barrier function and mechanotransduction.
Specifically, it regulates the exposure of EC surface adhesion molecules, acting as a
barrier to neutrophil adhesion and extravasation [25]. Metalloproteinases have been
shown to have the ability to cleave the glycocalyx, which is predominantly cleaved by
heparanase; however, the glycocalyx is only observed in vivo and appears to be absent in
vitro [25,159].
Further, while my studies assessed the PMVEC expression of each TIMP under
basal and septic conditions, it lacked a comprehensive analysis of metalloproteinase
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expression. Specifically, my study focused on three MMPs and two ADAMs; however,
metalloproteinases are an incredibly diverse group of enzymes. Finally, while I assessed
metalloproteinase and Timp mRNA expression, I did not examine metalloproteinase and
TIMP protein levels specifically due to a lack of available suitable antibodies. This
analysis of metalloproteinase activity was used as a surrogate for examining
metalloproteinase and TIMP protein levels as the balance between these components is
critical to metalloproteinase activity; however, further analysis of the activity of specific
metalloproteinases and the use of specific inhibitors is required.

4.3.2

Future Directions
In future studies, barrier dysfunction in septic WT PMVEC must be further

characterized in vitro to define the TIMP-dependent mechanisms promoting normal
PMVEC barrier function and protecting against septic PMVEC barrier dysfunction. Thus,
comprehensive expression and protein analysis of other members of the MMP and
ADAM families must be investigated combined with the use of specific activity assays
and inhibitors. Further, the use of PMVEC with genetically modified expression of
metalloproteinases (i.e. PMVEC isolated from mice genetically deficient, use of siRNA)
and more specific MMP/ADAM inhibitors will be required to comprehensively assess
their functional role. It will also be critical to utilize mice lacking specific
metalloproteinases and TIMPs to confirm my in vitro studies using in vivo models of
sepsis.
The reduced quantity of cell surface ICAM1 in Timp3-/- PMVEC should also be
further addressed by determining total (cytosolic combined with cell surface) ICAM1
protein expression. If total ICAM1 protein is significantly reduced compared to WT
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PMVEC, it suggests there is a disruption in the translational process, whereas if total
ICAM1 protein in Timp3-/- PMVEC is similar to WT PMVEC, it suggests that the protein
is effectively being synthesized, but that localization to the cell surface under basal
conditions is impaired. Interestingly, while the mechanisms mediating the decreased
ICAM1 on the cell surface of Timp3-/- PMVEC is unknown, it is important to note that
the increase in ICAM1 on the cell surface of Timp3-/- PMVEC under septic conditions
does suggest that Timp3-/- PMVEC have the ability to produce and localize ICAM1
protein to the cell surface.
In addition, while these studies utilized synthetic global metalloproteinase
inhibitors, the use of rTIMP3 is required to confirm the specific role of TIMP3 in both
microvascular leak as well as PMN-PMVEC interaction. This is important as injection of
rTIMP3 has been reported to decrease vascular leak across the blood-brain barrier in a
model of traumatic brain injury [80].
This investigation also focused solely on the metalloproteinase-dependent role of
TIMPs in PMVEC barrier dysfunction. There is, however, evidence for several
metalloproteinase-independent mechanisms. TIMPs have been found to interact directly
with cell surface receptors to activate the receptor and initiate cell signalling (i.e., TIMP1
binds CD63 and β1 integrin to promote epithelial cell proliferation and inhibit apoptosis)
[160]. Further, TIMP3 inhibits angiogenesis by binding to the VEGF receptor and
blocking VEGF-VEGFR2 interactions [88,90]. Similarly, TIMP3 also binds the ANG II
type 2 receptor, inhibiting HUVEC proliferation and angiogenesis through inhibition of
PKC and eNOS [155]. Thus, for example, future characterization of the VEGF signalling
pathway in WT and Timp3-/- PMVEC under basal and septic conditions would allow for

96

direct examination of the role of TIMP3-dependent VEGFR2 phosphorylation in basal
EC permeability and septic EC barrier dysfunction.
Solely male murine PMVEC were used for the current study; however, there is
much evidence of sex specific differences in human sepsis (i.e. septic females are less
susceptible to organ dysfunction and death). Men are more likely to have a 372 T/C
genetic polymorphism on the TIMP1 gene, which is associated with a higher risk of
severe sepsis and mortality [161]. Further, plasma levels of MMP3 were significantly
higher in male patients with severe bacterial sepsis compared to female patients [162].
Finally, men with severe bacterial sepsis represented a greater percentage of carriers of
MMP3 single nucleotide polymorphism allele 6A [162]. Thus, it would be interesting to
examine whether there are differences in the roles of metalloproteinases and TIMPs.
Preliminary mRNA expression data suggests that overall basal expression of Timps,
metalloproteinases, and cell surface proteins are similar in both sexes; however, there are
some trends towards sex-linked differences (Figure 4-1).
Lastly, all experiments were conducted using murine cells, and as such, human
cells must be employed in future studies to investigate this endogenous TIMP-dependent
mechanism promoting basal PMVEC barrier function in vitro, as well as potential
involvement in septic PMVEC barrier dysfunction. These studies would provide an
opportunity to assess in human PMVEC the molecular mechanisms regulating normal
and septic microvascular permeability that I have identified in murine PMVEC, which
will give further insight regarding the physiological relevance of these findings, as well
as provide strong clinical relevance.
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Figure 4-1: Septic changes in TIMP and metalloproteinase expression are different
in female vs. male PMVEC. Compared to naive male mice, Timp and metalloproteinase
mRNA expression is relatively similar in naïve female mice. Compared to 4h CLP male
mice, Timp and metalloproteinase mRNA expression is significantly altered or appears to
be altered in 4h CLP female mice; specifically, Timp1, -2, -3, Mmp2, -9, Adam17, Icam,
Vcam, Sele. * p<0.05 vs. male, Two-Way ANOVA followed by a Bonferroni post-hoc
test, n=4-8.
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4.4 Summary and Conclusions
In conclusion, I have identified a disruption in the TIMP/metalloproteinase
balance, leading to increases in specific TIMP and metalloproteinase expression and
metalloproteinase activity associated with septic PMVEC barrier dysfunction. This septic
PMVEC barrier dysfunction is based on a metalloproteinase-dependent mechanism,
potentially mediated through ADAM17, resulting in increased microvascular
permeability. In addition, Timp3-/- PMVEC have reduced ICAM1 on their cell surface,
which may be associated with impaired PMN recruitment. Based on my results, I believe
PMVEC-derived TIMPs support normal pulmonary microvascular endothelial barrier
function via metalloproteinase-dependent mechanisms, through the direct inhibition of
metalloproteinase activity, but also through metalloproteinase-independent mechanisms,
via regulation of PMN-PMVEC interactions (Figure 4-2). A better understanding of the
TIMP-mediated endogenous protective mechanism against septic PMVEC barrier
dysfunction would support new therapeutic interventions in human sepsis and related
septic organ dysfunction, as well as help eliminate PMVEC dysfunction in other vascular
diseases.
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Figure 4-2: Disruption in the balance between metalloproteinases and tissue
inhibitors of metalloproteinases leads to PMVEC activation and dysfunction. (A)
Septic PMVEC barrier dysfunction is based on a metalloproteinase-dependent
mechanism, resulting in increased microvascular permeability. (B) PMN-PMVEC
adhesion increased under septic conditions due to activation of cell adhesion molecules.
(C) In the absence of TIMP3 (Timp3-/-) cell surface ICAM1 is reduced on the cell surface
under basal and septic conditions, which may be associated with impaired PMN
recruitment; however, it appears to be through a metalloproteinase-independent
mechanism.
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